

Giuseppe SAGLIO - Curriculum Vitae	
Name Giuseppe SAGLIO	Position Full Professor of Hematology University of Turin

Date of Birth 17/05/50	Date of Doctoral Degree 23/07/1975
Doctoral Degree Medical Doctor	

Education and Training (include degrees and post-doctoral training)			
Institution and Location	Degree	Years	Field of Study
University of Turin	M.D.	1969-1975	Medicine
University of Turin	Residency	1975-1980	Internal Medicine
University of Milan	Residency	1980-1983	Hematology
University of Leiden	Fellow	1976	Molecular Biology
Inserm-Creteil, Paris	Fellow	1979	Molecular Biology
University of California, San Francisco	Fellow	1983	Molecular Biology

RESEARCH AND PROFESSIONAL EXPERIENCE:

NAME : Giuseppe SAGLIO

TITLES : MD, Professor of Internal Medicine and of Haematology

PROFESSIONAL EXPERIENCE :

1975 Degree in Medicine at the University of Turin

1975-1980 Residency in Internal Medicine at the University of Turin

1980-1983 Residency in Hematology at the University of Milan

1983-1990 Assistent Professor in Internal Medicine – University of Turin

1990- present Full Professor in Internal Medicine – University of Perugia (90/91), University of Turin in Turin in Novara (91/98), University of Turin in Turin (98-present)

1996-1999 Director of the I School in Internal Medicine of the University “Amedeo Avogadro” of Eastern Piedmont (formerly University of Turin in Novara) .

1996-1999 Coordinator of the PhD program in Molecular Medicine of the University “Amedeo Avogadro” of Eastern Piedmont (formerly University of Turin in Novara)

2000 – 2004 Vice-Dean of the Faculty of Medicine of the University of Turin

2001-2006 President of the II School of Medicine of the University of Turin

PRESENT APPOINTMENTS

Director of the Department of Internal Medicine of the San Luigi University Hospital of Turin

Director of the Division of Hematology at the Mauriziano Hospital– University of Turin.

HONORS:

President (1996-98) and past-president (1998-2000) of the Italian Society of Experimental Hematology (SIES).

Member of the Academy of Medicine of Turin

Member of the SAG Oncology Board of EMA (London) 2011-2014

Nominated Knight of the Italian Republic in 2107 for scientific merits

RESEARCH ACTIVITY:

Focused in molecular biology applied to clinical medicine in haematology. More that 500 peer reviewed publications with a total IF of > 4000. HI Scopus 77

EDITORIAL anACTIVITY

- Editorial Board of Journal of Clinical Oncology and Leukemia
- Referee for Journal of Clinical Oncology, Blood, British Journal of Hematology, Leukemia, Bone Marrow Transplantation, European Journal of Hematology, Haematologica and others;
- Reviewer for grants for the Leukemia Research Fund (UK), for MIUR, CNR and several Italian and European Universities (Padova, Siena, Jerusalem, Southampton, Salamanca, Cordoba etc...)

CLINICAL EXPERIENCE

Long standing clinical experience in running clinical trials under GCP rules

- 1: Talpaz M, Saglio G, Atallah E, Rousselot P. Dasatinib dose management for the treatment of chronic myeloid leukemia. *Cancer*. 2018 Jan 25. doi: 10.1002/cncr.31232. [Epub ahead of print]
- 2: Galimberti S, Bucelli C, Arrigoni E, Baratè C, Grassi S, Ricci F, Guerrini F, Ciabatti E, Fava C, D'Avolio A, Fontanelli G, Cambrin GR, Isidori A, Loscocco F, Caocci G, Greco M, Bocchia M, Aprile L, Gozzini A, Scappini B, Cattaneo D, Scortechini AR, La Nasa G, Bosi A, Leoni P, Danesi R, Saglio G, Visani G, Cortelezzi A, Petrini M, Iurlo A, Di Paolo A. The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia. *Oncotarget*. 2017 Sep 30;8
- 3: Saglio G, Jabbour E. First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI. *Leuk Lymphoma*. 2017 Oct 3:1-16.
- 4: Iurlo A, Galimberti S, Abruzzese E, Annunziata M, Bonifacio M, Latagliata R, Pregno P, Ferrero D, Sorà F, Orlandi EM, Fava C, Cattaneo D, Bucelli C, Binotto G, Pungolino E, Tiribelli M, Gozzini A, Gugliotta G, Castagnetti F, Stagno F, Rege-Cambrin G, Martino B, Luciano L, Breccia M, Sica S, Bocchia M, Pane F, Saglio G, Rosti G, Specchia G, Cortelezzi A, Baccarani M. Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. *Ann Hematol*. 2018 Jan;97(1):95-100.
- 5: Dogliotti I, Fava C, Serra A, Gottardi E, Daraio F, Carnuccio F, Giugliano E, Bocchia M, Saglio G, Rege-Cambrin G. CALR-positive myeloproliferative disorder in a patient with Ph-positive chronic myeloid leukemia in durable treatment-free remission: a case report. *Stem Cell Investig*. 2017 Jun 23;4:57.
- 6: Casnici C, Crotta K, Volpe G, Panuzzo C, Lattuada D, Mesiano G, Saglio G, Marelli O. Specific Monoclonal Antibody Against Bcr/Abl Out-of-Frame Alternative Proteins as Diagnostic Tool in Chronic Myelogenous Leukemia Patients. *Monoclon Antib Immunodiagn Immunother*. 2017 Aug;36(4):149-156.
- 7: Baccarani M, Pane F, Rosti G, Russo D, Saglio G. Chronic myeloid leukemia: room for improvement? *Haematologica*. 2017 Jul;102(7):1131-1133.
- 8: Santini V, Allione B, Zini G, Gioia D, Lunghi M, Poloni A, Cilloni D, Sanna A, Masiera E, Ceccarelli M, Abdel-Wahab O, Terenzi A, Angelucci E, Finelli C, Onida F, Pelizzari A, Ferrero D, Saglio G, Figueroa M, Levis A. A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. *Leukemia*. 2017 Jun 13.
- 9: Fava C, Saglio G. The biology of CML supports second-generation TKIs as frontline treatment. *Clin Adv Hematol Oncol*. 2017 Apr;15(4):302-307.
- 10: Gugliotta G, Castagnetti F, Breccia M, Albano F, Iurlo A, Intermesoli T, Abruzzese E, Levato L, D'Adda M, Pregno P, Cavazzini F, Stagno F, Martino B, La Barba G, Sorà F, Tiribelli M, Bigazzi C, Binotto G, Bonifacio M, Caracciolo C, Soverini S, Foà R, Cavo M, Martinelli G, Pane F, Saglio G, Baccarani M, Rosti G; Gruppo Italiano Malattie Ematologiche dell'Adulto - Chronic Myeloid Leukemia Working Party. Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia. *Haematologica*. 2017 Sep;102(9):1530-1536.
- 11: Pellegrino RM, Riondato F, Ferbo L, Boero M, Palmieri A, Osella L, Pollicino P, Miniscalco B, Saglio G, Roetto A. Altered Erythropoiesis in Mouse Models of Type 3 Hemochromatosis. *Biomed Res Int*. 2017;2017:2408941.

- 12: Saglio G, le Coutre P, Cortes J, Mayer J, Rowlings P, Mahon FX, Kroog G, Gooden K, Subar M, Shah NP. Evaluation of cardiovascular ischemic event rates in dasatinib-treated patients using standardized incidence ratios. *Ann Hematol.* 2017 Aug;96(8):1303-1313.
- 13: Messa E, Biale L, Castiglione A, Lunghi M, Bonferroni M, Salvi F, Allione B, Ferrero D, Calabrese C, De Gobbi M, Nicoli P, Gioia D, Levis A, Saglio G, Cilloni D. Erythroid response during iron chelation therapy in a cohort of patients affected by hematologic malignancies and aplastic anemia with transfusion requirement and iron overload: a FISM Italian multicenter retrospective study. *Leuk Lymphoma.* 2017 Nov;58(11):2752-2754.
- 14: Castagnetti F, Gugliotta G, Breccia M, Iurlo A, Levato L, Albano F, Vigneri P, Abruzzese E, Rossi G, Rupoli S, Cavazzini F, Martino B, Orlandi E, Pregno P, Annunziata M, Usala E, Tiribelli M, Sica S, Bonifacio M, Fava C, Gherlinzoni F, Bocchia M, Soverini S, Bochicchio MT, Cavo M, Giovanni M, Saglio G, Pane F, Baccarani M, Rosti G; GIMEMA CML Working Party. The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib. *Am J Hematol.* 2017 Aug;92(8):797-805.
- 15: Carrà G, Panuzzo C, Torti D, Parvis G, Crivellaro S, Familiari U, Volante M, Morena D, Lingua MF, Brancaccio M, Guerrasio A, Pandolfi PP, Saglio G, Taulli R, Morotti A. Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones. *Oncotarget.* 2017 May 30;8(22):35508-35522.
- 16: Caivano A, La Rocca F, Laurenzana I, Annese T, Tamma R, Familiari U, Simeon V, Trino S, De Luca L, Villani O, Berardi S, Basile A, Vacca A, Saglio G, Del Vecchio L, Musto P, Cilloni D. Epha3 acts as proangiogenic factor in multiple myeloma. *Oncotarget.* 2017 May 23;8(21):34298-34309.
- 17: Morotti A, Crivellaro S, Panuzzo C, Carrà G, Guerrasio A, Saglio G. I κ B- α : At the crossroad between oncogenic and tumor-suppressive signals. *Oncol Lett.* 2017 Feb;13(2):531-534.
- 18: Galeotti L, Ceccherini F, Domingo D, Laurino M, Polillo M, Di Paolo A, Baratè C, Fava C, D'Avolio A, Cervetti G, Guerrini F, Fontanelli G, Ciabatti E, Grassi S, Arrigoni E, Danesi R, Petrini M, Cornolti F, Saglio G, Galimberti S. Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia. *Cancer Chemother Pharmacol.* 2017 Apr;79(4):767-773.
- 19: Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ; IRIS Investigators. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. *N Engl J Med.* 2017 Mar 9;376(10):917-927. doi: 10.1056/NEJMoa1609324. PubMed PMID: 28273028.
- 20: Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, Gómez Casares MT, Hellmann A, Stentoft J, Conneally E, García-Gutiérrez V, Gattermann N, Wiktor-Jedrzejczak W, le Coutre PD, Martino B, Saussele S, Menssen HD, Deng W, Krunic N, Bedoucha V, Saglio G. Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. *Leukemia.* 2017 Jul;31(7):1525-1531.
- 21: Marconi C, Canobbio I, Bozzi V, Pippucci T, Simonetti G, Melazzini F, Angori S, Martinelli G, Saglio G, Torti M, Pastan I, Seri M, Pecci A. 5'UTR point substitutions and N-terminal truncating mutations of ANKRD26 in acute myeloid leukemia. *J Hematol Oncol.* 2017 Jan 18;10(1):18. doi: 10.1186/s13045-016-0382-y.

PubMed PMID: 28100250.

2 2: Rosso V, Petiti J, Bracco E, Pedrola R, Carnuccio F, Signorino E, Carturan S, Calabrese C, Bot-Sartor G, Ronconi M, Serra A, Saglio G, Frassoni F, Cilloni D. A novel assay to detect calreticulin mutations in myeloproliferative neoplasms. *Oncotarget*. 2016 Dec 23. doi: 10.18632/oncotarget.14113. [Epub ahead of print] PubMed PMID: 28031530.

3: Houshmand M, Soleimani M, Atashi A, Saglio G, Abdollahi M, Nikougoftar Zarif M. Mimicking the Acute Myeloid Leukemia Niche for Molecular Study and Drug Screening. *Tissue Eng Part C Methods*. 2017 Jan 13. doi: 10.1089/ten.TEC.2016.0404. [Epub ahead of print] PubMed PMID: 28007011.

4: Giona F, Saglio G, Santopietro M, Menna G, Putti MC, Micalizzi C, Iaria G, Santoro N, Ladogana S, Mura R, Burnelli R, Consarino C, Cosmi C, Moleti ML, Leszl A, Tucci F, Nanni M, Diverio D, Biondi A, Locatelli F, Foà R. Early response does not predict outcome in children and adolescents with chronic myeloid leukaemia treated with high-dose imatinib. *Br J Haematol*. 2016 Dec 16. doi: 10.1111/bjh.14458. [Epub ahead of print] PubMed PMID: 27984633.

5: Carrà G, Crivellaro S, Taulli R, Guerrasio A, Saglio G, Morotti A. Mechanisms of p53 Functional De-Regulation: Role of the I κ B- α /p53 Complex. *Int J Mol Sci*. 2016 Nov 29;17(12). pii: E1997. PubMed PMID: 27916821; PubMed Central PMCID: PMC5187797.

6: Carrà G, Panuzzo C, Crivellaro S, Morena D, Taulli R, Guerrasio A, Saglio G, Morotti A. The targetable role of herpes virus-associated ubiquitin-specific protease (HAUSP) in p190 BCR-ABL leukemia. *Oncol Lett*. 2016 Nov;12(5):3123-3126. PubMed PMID: 27899971; PubMed Central PMCID: PMC5103907.

7: Morotti A, Rocca S, Carrà G, Saglio G, Brancaccio M. Modeling myeloproliferative neoplasms: From mutations to mouse models and back again. *Blood Rev*. 2016 Nov 24. pii: S0268-960X(16)30034-0. doi: 10.1016/j.blre.2016.11.004. [Epub ahead of print] Review. PubMed PMID: 27899218.

8: Carturan S, Petiti J, Rosso V, Calabrese C, Signorino E, Bot-Sartor G, Nicoli P, Gallo D, Bracco E, Morotti A, Panuzzo C, Gottardi E, Frassoni F, Saglio G, Cilloni D. Variable but consistent pattern of Meningioma 1 gene (MN1) expression in different genetic subsets of acute myelogenous leukaemia and its potential use as a marker for minimal residual disease detection. *Oncotarget*. 2016 Nov 8;7(45):74082-74096. doi: 10.18632/oncotarget.12269. PubMed PMID: 27765915.

9: Mizzi C, Dalabira E, Kumuthini J, Dzimiri N, Balogh I, Başak N, Böhm R, Borg

J, Borgiani P, Bozina N, Bruckmueller H, Burzynska B, Carracedo A, Cascorbi I, Deltas C, Dolzan V, Fenech A, Grech G, Kasiulevicius V, Kádaši L, Kučinskas V, Khusnutdinova E, Loukas YL, Macek M Jr, Makukh H, Mathijssen R, Mitropoulos K, Mitropoulou C, Novelli G, Papantoni I, Pavlovic S, Saglio G, Setric J, Stojiljkovic M, Stubbs AP, Squassina A, Torres M, Turnovec M, van Schaik RH, Voskarides K, Wakil SM, Werk A, Del Zompo M, Zukic B, Katsila T, Lee MT, Motsinger-Rief A, McLeod HL, van der Spek PJ, Patrinos GP. A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics. *PLoS One*. 2016 Sep 16;11(9):e0162866. doi: 10.1371/journal.pone.0162866. PubMed PMID: 27636550; PubMed Central PMCID: PMC5026342.

10: Guaraldo M, Santambrogio P, Rovelli E, Di Savino A, Saglio G, Cittaro D, Roetto A, Levi S. Characterization of human mitochondrial ferritin promoter: identification of transcription factors and evidences of epigenetic control. *Sci Rep*. 2016 Sep 14;6:33432. doi: 10.1038/srep33432. PubMed PMID: 27625068; PubMed Central PMCID: PMC5022048.

11: Iurlo A, Nobili A, Latagliata R, Bucelli C, Castagnetti F, Breccia M, Abruzzese E, Cattaneo D, Fava C, Ferrero D, Gozzini A, Bonifacio M, Tiribelli M, Pregno P, Stagno F, Vigneri P, Annunziata M, Cavazzini F, Binotto G, Mansueto G, Russo S, Falzetti F, Montefusco E, Gugliotta G, Storti S, D'Addosio AM, Scaffidi L, Cortesi L, Cedrone M, Rossi AR, Avanzini P, Mauro E, Spadea A, Celesti F, Giglio G, Isidori A, Crugnola M, Calistri E, Sorà F, Rege-Cambrin G, Sica S, Luciano L, Galimberti S, Orlandi EM, Bocchia M, Tettamanti M, Alimena G, Saglio G, Rosti G, Mannucci PM, Cortelezzi A. Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. *Oncotarget*. 2016 Nov 29;7(48):80083-80090. doi: 10.18632/oncotarget.11657. PubMed PMID: 27579540.

12: Carrà G, Torti D, Crivellaro S, Panuzzo C, Tauli R, Cilloni D, Guerrasio A, Saglio G, Morotti A. The BCR-ABL/NF- κ B signal transduction network: a long lasting relationship in Philadelphia positive Leukemias. *Oncotarget*. 2016 Oct 4;7(40):66287-66298. doi: 10.18632/oncotarget.11507. Review. PubMed PMID: 27563822.

13: Soverini S, De Benedittis C, Castagnetti F, Gugliotta G, Mancini M, Bavaro L, Machova Polakova K, Linhartova J, Iurlo A, Russo D, Pane F, Saglio G, Rosti G, Cavo M, Baccarani M, Martinelli G. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants. *BMC Cancer*. 2016 Aug 2;16:572. doi: 10.1186/s12885-016-2635-0. PubMed PMID: 27485109; PubMed Central PMCID: PMC4970247.

14: Pellegrino RM, Boda E, Montarolo F, Boero M, Mezzanotte M, Saglio G, Buffo A, Roetto A. Transferrin Receptor 2 Dependent Alterations of Brain Iron Metabolism Affect Anxiety Circuits in the Mouse. *Sci Rep*. 2016 Aug 1;6:30725. doi:

10.1038/srep30725. PubMed PMID: 27477597; PubMed Central PMCID: PMC4967901.

15: Castagnetti F, Breccia M, Gugliotta G, Martino B, D'Adda M, Stagno F, Carella AM, Avanzini P, Tiribelli M, Trabacchi E, Visani G, Gobbi M, Salvucci M, Levato L, Binotto G, Capalbo SF, Bochicchio MT, Soverini S, Cavo M, Martinelli G, Alimena G, Pane F, Saglio G, Rosti G, Baccarani M; GIMEMA CML Working Party.. Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. *Haematologica*. 2016 Oct;101(10):1200-1207. PubMed PMID: 27470600; PubMed Central PMCID: PMC5046649.

16: Morotti A, Torti D, Carrà G, Panuzzo C, Crivellaro S, Taulli R, Fava C, Guerrasio A, Saglio G. Unleashing the Guardian: The Targetable BCR-ABL/HAUSP/PML/PTEN Network in Chronic Myeloid Leukemia. *Curr Drug Targets*. 2016 Jun 8. [Epub ahead of print] PubMed PMID: 27291926.

17: Mughal TI, Abdel-Wahab O, Rampal R, Mesa R, Koschmieder S, Levine R, Hehlmann R, Saglio G, Barbui T, Van Etten RA. Contemporary insights into the pathogenesis and treatment of chronic myeloproliferative neoplasms. *Leuk Lymphoma*. 2016 Jul;57(7):1517-26. doi: 10.1080/10428194.2016.1185783. PubMed PMID: 27240645.

18: Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, Shah NP, Chuah C, Casanova L, Bradley-Garelik B, Manos G, Hochhaus A. Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial. *J Clin Oncol*. 2016 Jul 10;34(20):2333-40. doi: 10.1200/JCO.2015.64.8899. PubMed PMID: 27217448; PubMed Central PMCID: PMC5118045.

19: Shah NP, Rousselot P, Schiffer C, Rea D, Cortes JE, Milone J, Mohamed H, Healey D, Kantarjian H, Hochhaus A, Saglio G. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034. *Am J Hematol*. 2016 Sep;91(9):869-74. doi: 10.1002/ajh.24423. PubMed PMID: 27192969; PubMed Central PMCID: PMC5094534.

20: Crivellaro S, Carrà G, Panuzzo C, Taulli R, Guerrasio A, Saglio G, Morotti A. The non-genomic loss of function of tumor suppressors: an essential role in the pathogenesis of chronic myeloid leukemia chronic phase. *BMC Cancer*. 2016 May 16;16:314. doi: 10.1186/s12885-016-2346-6. Review. PubMed PMID: 27184141; PubMed Central PMCID: PMC4869339.

21: Gallo D, Nicoli P, Calabrese C, Gaidano V, Petiti J, Rosso V, Signorino E, Carturan S, Bot-Sartor G, Volpe G, Frassoni F, Saglio G, Cilloni D. The Wilms' tumor (WT1) gene expression correlates with the International Prognostic Scoring System (IPSS) score in patients with myelofibrosis and it is a marker of response to therapy. *Cancer Med*. 2016 Jul;5(7):1650-3. doi: 10.1002/cam4.735. PubMed PMID:

27167495; PubMed Central PMCID: PMC4867666.

22: Mughal TI, Radich JP, Deininger MW, Apperley JF, Hughes TP, Harrison CJ, Gambacorti-Passerini C, Saglio G, Cortes J, Daley GQ. Chronic myeloid leukemia: reminiscences and dreams. *Haematologica*. 2016 May;101(5):541-58. doi: 10.3324/haematol.2015.139337. Review. PubMed PMID: 27132280; PubMed Central PMCID: PMC5004358.

23: Fava C, Rege-Cambrin G, Dogliotti I, Gottardi E, Berchiolla P, Di Gioacchino B, Crasto F, Lorenzatti R, Volpengo A, Daraio F, Fantino C, Saglio G. Early BCR-ABL1 Reduction Is Predictive of Better Event-free Survival in Patients With Newly Diagnosed Chronic Myeloid Leukemia Treated With Any Tyrosine Kinase Inhibitor. *Clin Lymphoma Myeloma Leuk*. 2016 Aug;16 Suppl:S96-S100. doi: 10.1016/j.clml.2016.03.008. Review. PubMed PMID: 27131622.

24: Cross NC, White HE, Ernst T, Welden L, Dietz C, Saglio G, Mahon FX, Wong CC, Zheng D, Wong S, Wang SS, Akiki S, Albano F, Andrikovics H, Anwar J, Balatzenko G, Bendit I, Beveridge J, Boeckx N, Cerveira N, Cheng SM, Colomer D, Czurda S, Daraio F, Dulucq S, Eggen L, El Housni H, Gerrard G, Gniot M, Izzo B, Jacquin D, Janssen JJ, Jeromin S, Jurcek T, Kim DW, Machova-Polakova K, Martinez-Lopez J, McBean M, Mesanovic S, Mitterbauer-Hohendanner G, Mobtaker H, Mozziconacci MJ, Pajič T, Pallisgaard N, Panagiotidis P, Press RD, Qin YZ, Radich J, Sacha T, Touloumenidou T, Waits P, Wilkinson E, Zadro R, Müller MC, Hochhaus A, Branford S. Development and evaluation of a secondary reference panel for BCR-ABL1 quantification on the International Scale. *Leukemia*. 2016 Sep;30(9):1844-52. doi: 10.1038/leu.2016.90. PubMed PMID: 27109508.

25: Fava C, Saglio G. Ponatinib for chronic myeloid leukaemia: future perspectives. *Lancet Oncol*. 2016 May;17(5):546-7. doi: 10.1016/S1470-2045(16)30064-X. PubMed PMID: 27083331.

26: Schiffer CA, Cortes JE, Hochhaus A, Saglio G, le Coutre P, Porkka K, Mustjoki S, Mohamed H, Shah NP. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity. *Cancer*. 2016 May 1;122(9):1398-407. doi: 10.1002/cncr.29933. PubMed PMID: 26998677; PubMed Central PMCID: PMC5071708.

27: Gugliotta G, Castagnetti F, Breccia M, Gozzini A, Usala E, Carella AM, Rege-Cambrin G, Martino B, Abruzzese E, Albano F, Stagno F, Luciano L, D'Adda M, Bocchia M, Cavazzini F, Tiribelli M, Lunghi M, Pia Falcone A, Musolino C, Levato L, Venturi C, Soverini S, Cavo M, Alimena G, Pane F, Martinelli G, Saglio G, Rosti G, Baccarani M; GIMEMA CML Working Party.. Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia. *Am J Hematol*. 2016 Jun;91(6):617-22. doi: 10.1002/ajh.24362. PubMed PMID: 26971721.

28: Di Savino A, Gaidano V, Palmieri A, Crasto F, Volpengo A, Lorenzatti R, Scaravaglio P, Manello A, Nicoli P, Gottardi E, Saglio G, Cilloni D, De Gobbi M. Clinical significance of TFR2 and EPOR expression in bone marrow cells in myelodysplastic syndromes. *Br J Haematol*. 2016 Feb 23. doi: 10.1111/bjh.13968. [Epub ahead of print] PubMed PMID: 26914246.

29: Giona F, Moleti ML, De Benedittis D, Santopietro M, Nanni M, Testi AM, Orlando S, Iori AP, Piciocchi A, Gottardi E, Barberi W, Diverio D, Saglio G, Foà R. Can chronic myeloid leukaemia in children and adolescents be successfully treated without haematopoietic stem cell transplant? A single centre experience. *Br J Haematol*. 2016 Jun;173(5):749-53. doi: 10.1111/bjh.13991. PubMed PMID: 26913809.

30: Saglio G, Fava C. BCR-ABL1 mutation \neq ponatinib resistance. *Blood*. 2016 Feb 11;127(6):666-7. doi: 10.1182/blood-2015-12-685149. PubMed PMID: 26869304.

31: Morotti A, Carrà G, Panuzzo C, Crivellaro S, Taulli R, Guerrasio A, Saglio G. Protein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive Leukemias. *Adv Hematol*. 2015;2015:612567. doi: 10.1155/2015/612567. Review. PubMed PMID: 26843864; PubMed Central PMCID: PMC4710905.

32: Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre PD, Etienne G, Dorlhiac-Llacer PE, Clark RE, Flinn IW, Nakamae H, Donohue B, Deng W, Dalal D, Menssen HD, Kantarjian HM. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. *Leukemia*. 2016 May;30(5):1044-54. doi: 10.1038/leu.2016.5. PubMed PMID: 26837842; PubMed Central PMCID: PMC4858585.

33: Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Döhner H, de Wit TD, Eichinger S, Fibbe W, Green T, de Haas F, Iolascon A, Jaffredo T, Rodeghiero F, Salles G, Schuringa JJ; EHA Roadmap for European Hematology Research.. The European Hematology Association Roadmap for European Hematology Research: a consensus document. *Haematologica*. 2016 Feb;101(2):115-208. doi: 10.3324/haematol.2015.136739. PubMed PMID: 26819058; PubMed Central PMCID: PMC4938336.

34: Morotti A, Panuzzo C, Crivellaro S, Carrà G, Torti D, Guerrasio A, Saglio G. The Role of PTEN in Myeloid Malignancies. *Hematol Rep*. 2015 Dec 9;7(4):5844. doi: 10.4081/hr.2015.6027. Review. PubMed PMID: 26734127; PubMed Central PMCID: PMC4691678.

35: Panuzzo C, Volpe G, Cibrario Rocchietti E, Casnici C, Crotta K, Crivellaro S, Carrà G, Lorenzatti R, Peracino B, Torti D, Morotti A, Camacho-Leal MP, Defilippi

P, Marelli O, Saglio G. New alternative splicing BCR/ABL-OOF shows an oncogenic role by lack of inhibition of BCR GTPase activity and an increased of persistence of Rac activation in chronic myeloid leukemia. *Oncoscience*. 2015 Nov 11;2(10):880-91. PubMed PMID: 26682280; PubMed Central PMCID: PMC4671955.

36: Breccia M, Stagno F, Luciano L, Abruzzese E, Annunziata M, D'Adda M, Maggi A, Sgherza N, Russo-Rossi A, Pregno P, Castagnetti F, Iurlo A, Latagliata R, Cedrone M, Di Renzo N, Sorà F, Rege-Cambrin G, La Nasa G, Scortechini AR, Greco G, Franceschini L, Sica S, Bocchia M, Crugnola M, Orlandi E, Guarini A, Specchia G, Rosti G, Saglio G, Alimena G. Dasatinib first-line: Multicentric Italian experience outside clinical trials. *Leuk Res*. 2016 Jan;40:24-9. doi: 10.1016/j.leukres.2015.11.008. PubMed PMID: 26643920.

37: Boero M, Pagliaro P, Tullio F, Pellegrino RM, Palmieri A, Ferbo L, Saglio G, De Gobbi M, Penna C, Roetto A. A comparative study of myocardial molecular phenotypes of two *tfr2* β null mice: role in ischemia/reperfusion. *Biofactors*. 2015 Sep-Oct;41(5):360-71. doi: 10.1002/biof.1237. PubMed PMID: 26458496.

38: Hochhaus A, Rosti G, Cross NC, Steegmann JL, le Coutre P, Ossenkoppele G, Petrov L, Masszi T, Hellmann A, Griskevicius L, Wiktor-Jedrzejczak W, Rea D, Coriu D, Brümmendorf TH, Porkka K, Saglio G, Gastl G, Müller MC, Schuld P, Di Matteo P, Pellegrino A, Dezzani L, Mahon FX, Baccarani M, Giles FJ. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study. *Leukemia*. 2016 Jan;30(1):57-64. doi: 10.1038/leu.2015.270. PubMed PMID: 26437782; PubMed Central PMCID: PMC4705425.

39: Crivellaro S, Panuzzo C, Carrà G, Volpengo A, Crasto F, Gottardi E, Familiari U, Papotti M, Torti D, Piazza R, Redaelli S, Tauli R, Guerrasio A, Saglio G, Morotti A. Non genomic loss of function of tumor suppressors in CML: BCR-ABL promotes $I\kappa B\alpha$ mediated p53 nuclear exclusion. *Oncotarget*. 2015 Sep 22;6(28):25217-25. doi: 10.18632/oncotarget.4611. PubMed PMID: 26295305; PubMed Central PMCID: PMC4694826.

40: Koren-Michowitz M, Shimoni A, Daraio F, Crasto F, Lorenzatti R, Volchek Y, Amariglio N, Gottardi E, Saglio G, Nagler A. Sensitive Replicate Real-Time Quantitative PCR of BCR-ABL Shows Deep Molecular Responses in Long-Term Post-Allogeneic Stem Cell Transplantation Chronic Myeloid Leukemia Patients. *Biol Blood Marrow Transplant*. 2015 Oct;21(10):1852-5. doi: 10.1016/j.bbmt.2015.06.018. PubMed PMID: 26151304.

41: Rosso V, Bracco E, Pedrola R, Carturan S, Signorino E, Petiti J, Calabrese C, Nicoli P, De Gobbi M, Gaidano V, Gallo D, Ulisciani S, Fava C, Rege-Cambrin G, Frassoni F, Saglio G, Cilloni D. Detection of BCR-ABL T315I mutation by peptide nucleic acid directed PCR clamping and by peptide nucleic acid FISH. *Biomark Res*. 2015 Jul 3;3:15. doi: 10.1186/s40364-015-0039-y. PubMed PMID: 26146560; PubMed

Central PMCID: PMC4490729.

42: Hughes TP, Saglio G, Quintás-Cardama A, Mauro MJ, Kim DW, Lipton JH, Bradley-Garelik MB, Ukropec J, Hochhaus A. BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase. *Leukemia*. 2015 Sep;29(9):1832-8. doi: 10.1038/leu.2015.168. PubMed PMID: 26118315; PubMed Central PMCID: PMC4559757.

43: Gugliotta G, Castagnetti F, Breccia M, Levato L, D'Adda M, Stagno F, Tiribelli M, Salvucci M, Fava C, Martino B, Cedrone M, Bocchia M, Trabacchi E, Cavazzini F, Usala E, Russo Rossi A, Bochicchio MT, Soverini S, Alimena G, Cavo M, Pane F, Martinelli G, Saglio G, Baccarani M, Rosti G; GIMEMA CML Working Party.. Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia. *Haematologica*. 2015 Sep;100(9):1146-50. doi: 10.3324/haematol.2015.129221. PubMed PMID: 26113419; PubMed Central PMCID: PMC4800682.

44: Guglielmelli T, Giugliano E, Brunetto V, Rapa I, Cappia S, Giorcelli J, Rrodhe S, Papotti M, Saglio G. mTOR pathway activation in multiple myeloma cell lines and primary tumour cells: pomalidomide enhances cytoplasmic-nuclear shuttling of mTOR protein. *Oncoscience*. 2015 Apr 6;2(4):382-94. PubMed PMID: 26097872; PubMed Central PMCID: PMC4468324.

45: Castagnetti F, Gugliotta G, Breccia M, Stagno F, Iurlo A, Albano F, Abruzzese E, Martino B, Levato L, Intermesoli T, Pregno P, Rossi G, Gherlinzoni F, Leoni P, Cavazzini F, Venturi C, Soverini S, Testoni N, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G, Baccarani M; GIMEMA CML Working Party.. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib. *Leukemia*. 2015 Sep;29(9):1823-31. doi: 10.1038/leu.2015.152. PubMed PMID: 26088952.

46: Nicoli P, Calabrese C, Pellegrino RM, Rosso V, Bracco E, Signorino E, Carturan S, Petit J, Gallo D, Gaidano V, De Gobbi M, Roetto A, Saglio G, Cilloni D. Development of cellular and humoral response against WT1 protein vaccination in mice. *Am J Hematol*. 2015 Sep;90(9):E193-4. doi: 10.1002/ajh.24092. PubMed PMID: 26088411; PubMed Central PMCID: PMC5054933.

47: Morotti A, Fava C, Saglio G. Milestones and monitoring. *Curr Hematol Malig Rep*. 2015 Jun;10(2):167-72. doi: 10.1007/s11899-015-0258-1. Review. PubMed PMID: 25921389; PubMed Central PMCID: PMC4445481.

48: Giona F, Putti MC, Micalizzi C, Menna G, Moleti ML, Santoro N, Iaria G, Ladogana S, Burnelli R, Consarino C, Varotto S, Tucci F, Messina C, Nanni M, Diverio D, Biondi A, Pession A, Locatelli F, Piciocchi A, Gottardi E, Saglio G,

Foà R. Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience. *Br J Haematol.* 2015 Aug;170(3):398-407. doi: 10.1111/bjh.13453. PubMed PMID: 25891192.

49: Fava C, Morotti A, Dogliotti I, Saglio G, Rege-Cambrin G. Update on emerging treatments for chronic myeloid leukemia. *Expert Opin Emerg Drugs.* 2015 Jun;20(2):183-96. doi: 10.1517/14728214.2015.1031217. Review. PubMed PMID: 25826695.

50: Fava C, Rege-Cambrin G, Saglio G. The choice of first-line chronic myelogenous leukemia treatment. *Ann Hematol.* 2015 Apr;94 Suppl 2:S123-31. doi: 10.1007/s00277-015-2321-3. Review. PubMed PMID: 25814078; PubMed Central PMCID: PMC4375302.

51: Wang J, Shen ZX, Saglio G, Jin J, Huang H, Hu Y, Du X, Li J, Meng F, Zhu H, Hu J, Wang J, Hou M, Hertle S, Menssen HD, Ortmann CE, Tribouley C, Yuan Y, Baccarani M, Huang X. Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. *Blood.* 2015 Apr 30;125(18):2771-8. doi: 10.1182/blood-2014-09-601674. PubMed PMID: 25766724; PubMed Central PMCID: PMC4416528.

52: Di Savino A, Panuzzo C, Rocca S, Familiari U, Piazza R, Crivellaro S, Carrà G, Ferretti R, Fusella F, Giugliano E, Camporeale A, Franco I, Miniscalco B, Cutrin JC, Turco E, Silengo L, Hirsch E, Rege-Cambrin G, Gambacorti-Passerini C, Pandolfi PP, Papotti M, Saglio G, Tarone G, Morotti A, Brancaccio M. Morgana acts as an oncosuppressor in chronic myeloid leukemia. *Blood.* 2015 Apr 2;125(14):2245-53. doi: 10.1182/blood-2014-05-575001. PubMed PMID: 25678499.

53: Cross NC, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E, Lange T, Lion T, Machova Polakova K, Dulucq S, Martinelli G, Oppliger Leibundgut E, Pallisgaard N, Barbany G, Sacha T, Talmaci R, Izzo B, Saglio G, Pane F, Müller MC, Hochhaus A. Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia. *Leukemia.* 2015 May;29(5):999-1003. doi: 10.1038/leu.2015.29. Review. PubMed PMID: 25652737; PubMed Central PMCID: PMC4430701.

54: Morotti A, Panuzzo C, Crivellaro S, Carrà G, Fava C, Guerrasio A, Pandolfi PP, Saglio G. BCR-ABL inactivates cytosolic PTEN through Casein Kinase II mediated tail phosphorylation. *Cell Cycle.* 2015;14(7):973-9. doi: 10.1080/15384101.2015.1006970. PubMed PMID: 25608112; PubMed Central PMCID: PMC4615112.

55: Cortes J, Mauro M, Steegmann JL, Saglio G, Malhotra R, Ukropec JA, Wallis NT. Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL

inhibitors: Data from the FDA Adverse Event Reporting System. *Am J Hematol.* 2015 Apr;90(4):E66-72. doi: 10.1002/ajh.23938. PubMed PMID: 25580915.

56: Kaeda J, Ringel F, Oberender C, Mills K, Quintarelli C, Pane F, Koschmieder S, Slany R, Schwarzer R, Saglio G, Hemmati P, van Lessen A, Amini L, Gresse M, Vagge E, Burmeister T, Serra A, Carson A, Schwarz M, Westermann J, Jundt F, Dörken B, le Coutre P. Up-regulated MSI2 is associated with more aggressive chronic myeloid leukemia. *Leuk Lymphoma.* 2015 Jul;56(7):2105-13. doi: 10.3109/10428194.2014.981175. PubMed PMID: 25363400.

57: Castagnetti F, Gugliotta G, Bacarani M, Breccia M, Specchia G, Levato L, Abruzzese E, Rossi G, Iurlo A, Martino B, Pregno P, Stagno F, Cuneo A, Bonifacio M, Gobbi M, Russo D, Gozzini A, Tiribelli M, de Vivo A, Alimena G, Cavo M, Martinelli G, Pane F, Saglio G, Rosti G; GIMEMA CML Working Party.. Differences among young adults, adults and elderly chronic myeloid leukemia patients. *Ann Oncol.* 2015 Jan;26(1):185-92. doi: 10.1093/annonc/mdu490. PubMed PMID: 25361995.

58: Gambacorti-Passerini CB, Donadoni C, Parmiani A, Pirola A, Redaelli S, Signore G, Piazza V, Malcovati L, Fontana D, Spinelli R, Magistrone V, Gaipa G, Peronaci M, Morotti A, Panuzzo C, Saglio G, Usala E, Kim DW, Rea D, Zervakis K, Viniou N, Symeonidis A, Becker H, Boulwood J, Campiotti L, Carrabba M, Elli E, Bignell GR, Papaemmanuil E, Campbell PJ, Cazzola M, Piazza R. Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. *Blood.* 2015 Jan 15;125(3):499-503. doi: 10.1182/blood-2014-06-579466. PubMed PMID: 25343957.

59: Panuzzo C, Crivellaro S, Carrà G, Guerrasio A, Saglio G, Morotti A. BCR-ABL promotes PTEN downregulation in chronic myeloid leukemia. *PLoS One.* 2014 Oct 24;9(10):e110682. doi: 10.1371/journal.pone.0110682. PubMed PMID: 25343485; PubMed Central PMCID: PMC4208795.

60: Mughal TI, Barbui T, Abdel-Wahab O, Kralovics R, Jamieson C, Kvasnicka HM, Mullaly A, Rampal R, Mesa R, Kiladjian JJ, Deininger M, Prchal J, Hehlmann R, Saglio G, Van Etten RA. Novel insights into the biology and treatment of chronic myeloproliferative neoplasms. *Leuk Lymphoma.* 2015 Jul;56(7):1938-48. doi: 10.3109/10428194.2014.974594. Review. PubMed PMID: 25330439; PubMed Central PMCID: PMC5076856.

61: Girmenia C, Rossolini GM, Piciocchi A, Bertaina A, Pisapia G, Pastore D, Sica S, Severino A, Cudillo L, Ciceri F, Scimè R, Lombardini L, Viscoli C, Rambaldi A; Gruppo Italiano Trapianto Midollo Osseo (GITMO).; Gruppo Italiano Trapianto Midollo Osseo GITMO.. Infections by carbapenem-resistant *Klebsiella pneumoniae* in SCT recipients: a nationwide retrospective survey from Italy. *Bone Marrow Transplant.* 2015 Feb;50(2):282-8. doi: 10.1038/bmt.2014.231. PubMed PMID: 25310302.

62: Giona F, Saglio G, Moleti ML, Piciocchi A, Rea M, Nanni M, Marzella D, Testi AM, Mariani S, Laurino M, Diverio D, Gottardi E, Foà R. Treatment-free remission after imatinib discontinuation is possible in paediatric patients with chronic myeloid leukaemia. *Br J Haematol*. 2015 Jan;168(2):305-8. doi: 10.1111/bjh.13103. PubMed PMID: 25160793.

63: Morotti A, Panuzzo C, Crivellaro S, Carrà G, Guerrasio A, Saglio G. HAUSP compartmentalization in chronic myeloid leukemia. *Eur J Haematol*. 2015 Apr;94(4):318-21. doi: 10.1111/ejh.12422. PubMed PMID: 25082234.

64: Aslanyan MG, Kroeze LI, Langemeijer SM, Koorenhof-Scheele TN, Massop M, van Hoogen P, Stevens-Linders E, van de Locht LT, Tönnissen E, van der Heijden A, da Silva-Coelho P, Cilloni D, Saglio G, Marie JP, Tang R, Labar B, Amadori S, Muus P, Willemze R, Marijt EW, de Witte T, van der Reijden BA, Suci S, Jansen JH. Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial. *Ann Hematol*. 2014 Aug;93(8):1401-12. doi: 10.1007/s00277-014-2055-7. PubMed PMID: 24994606.

65: Mughal TI, Vannucchi AM, Soverini S, Bazeos A, Tibes R, Saglio G, Abdel-Wahab O, Pardanani A, Hehlmann R, Barbui T, Van Etten R, Tefferi A, Goldman JM. Current pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms. *Haematologica*. 2014 May;99(5):797-801. doi: 10.3324/haematol.2013.097832. Review. PubMed PMID: 24790057; PubMed Central PMCID: PMC4008109.

66: Nai A, Pellegrino RM, Rausa M, Pagani A, Boero M, Silvestri L, Saglio G, Roetto A, Camaschella C. The erythroid function of transferrin receptor 2 revealed by Tmprss6 inactivation in different models of transferrin receptor 2 knockout mice. *Haematologica*. 2014 Jun;99(6):1016-21. doi: 10.3324/haematol.2013.103143. PubMed PMID: 24658816; PubMed Central PMCID: PMC4040905.

67: Shah NP, Guilhot F, Cortes JE, Schiffer CA, le Coutre P, Brümmendorf TH, Kantarjian HM, Hochhaus A, Rousselot P, Mohamed H, Healey D, Cunningham M, Saglio G. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. *Blood*. 2014 Apr 10;123(15):2317-24. doi: 10.1182/blood-2013-10-532341. PubMed PMID: 24569263; PubMed Central PMCID: PMC4915794.

68: Hughes TP, Hochhaus A, Kantarjian HM, Cervantes F, Guilhot F, Niederwieser D, le Coutre PD, Rosti G, Ossenkoppele G, Lobo C, Shibayama H, Fan X, Menssen HD, Kemp C, Larson RA, Saglio G. Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice

daily. *Haematologica*. 2014 Jul;99(7):1204-11. doi: 10.3324/haematol.2013.091272. PubMed PMID: 24532039; PubMed Central PMCID: PMC4077082.

69: Breccia M, Alimena G, Baccarani M, Bocchia M, Di Raimondo F, Gambacorti-Passerini C, Gozzini A, Morra E, Pane F, Pregno P, Rege-Cambrin G, Rosti G, Specchia G, Vigneri P, Saglio G. Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013. *Crit Rev Oncol Hematol*. 2014 Jun;90(3):181-9. doi: 10.1016/j.critrevonc.2013.12.010. PubMed PMID: 24405858.

70: Morotti A, Panuzzo C, Fava C, Saglio G. Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia. *Expert Opin Biol Ther*. 2014 Mar;14(3):287-99. doi: 10.1517/14712598.2014.867323. Review. PubMed PMID: 24387320.

71: Barosi G, Vannucchi AM, De Stefano V, Pane F, Passamonti F, Rambaldi A, Saglio G, Barbui T, Tura S. Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: a consensus-based SIE, SIES, GITMO position paper. *Leuk Res*. 2014 Feb;38(2):155-60. doi: 10.1016/j.leukres.2013.09.008. PubMed PMID: 24378116.

72: De Francia S, D'Avolio A, Ariaudo A, Pirro E, Piccione F, Simiele M, Fava C, Calcagno A, Di Perri G, Saglio G. Plasma and intracellular imatinib concentrations in patients with chronic myeloid leukemia. *Ther Drug Monit*. 2014 Jun;36(3):410-2. doi: 10.1097/FTD.000000000000013. PubMed PMID: 24342895.

73: Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G, Nakaseko C, De Souza CA, Kalaycio ME, Meier S, Fan X, Menssen HD, Larson RA, Hochhaus A. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. *Blood*. 2014 Feb 27;123(9):1353-60. doi: 10.1182/blood-2013-06-510396. PubMed PMID: 24335106; PubMed Central PMCID: PMC4624459.

74: Morotti A, Panuzzo C, Crivellaro S, Pergolizzi B, Familiari U, Berger AH, Saglio G, Pandolfi PP. BCR-ABL disrupts PTEN nuclear-cytoplasmic shuttling through phosphorylation-dependent activation of HAUSP. *Leukemia*. 2014 Jun;28(6):1326-33. doi: 10.1038/leu.2013.370. PubMed PMID: 24317448.

75: Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boqué C, Chuah C, Pavlovsky C, Mayer J, Cortes J, Baccarani M, Kim DW, Bradley-Garelik MB, Mohamed H, Wildgust M, Hochhaus A. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). *Blood*. 2014 Jan 23;123(4):494-500. doi: 10.1182/blood-2013-06-511592. PubMed PMID: 24311723; PubMed Central PMCID: PMC4190618.

76: Fava C, Rege-Cambrin G, Busca A, Gottardi E, Daraio F, Saglio G. Second-generation tyrosine kinase inhibitors can induce complete molecular response in Ph-positive acute lymphoblastic leukemia after allogeneic stem cell transplant. *Clin Lymphoma Myeloma Leuk*. 2013 Sep;13 Suppl 2:S272-5. doi: 10.1016/j.clml.2013.05.017. PubMed PMID: 24290212.

77: Quintarelli C, De Angelis B, Errichiello S, Caruso S, Esposito N, Colavita I, Raia M, Pagliuca S, Pugliese N, Risitano AM, Picardi M, Luciano L, Saglio G, Martinelli G, Pane F. Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia. *Leuk Res*. 2014 Feb;38(2):236-42. doi: 10.1016/j.leukres.2013.11.006. PubMed PMID: 24280282.

78: Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H; PACE Investigators.. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. *N Engl J Med*. 2013 Nov 7;369(19):1783-96. doi: 10.1056/NEJMoa1306494. PubMed PMID: 24180494; PubMed Central PMCID: PMC3886799.

79: Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E, Chiappella A, Baldini L, Rossi G, Pulsoni A, Di Raimondo F, Rigacci L, Pinto A, Galimberti S, Bari A, Rota-Scalabrini D, Ferrari A, Zaja F, Gallamini A, Specchia G, Musto P, Rossi FG, Gamba E, Evangelista A, Vitolo U; Fondazione Italiana Linfomi.. Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. *Blood*. 2013 Nov 28;122(23):3759-66. doi: 10.1182/blood-2013-06-507319. PubMed PMID: 24085766.

80: Savona MR, Saglio G. Identifying the time to change BCR-ABL inhibitor therapy in patients with chronic myeloid leukemia. *Acta Haematol*. 2013;130(4):268-78. doi: 10.1159/000353163. Review. PubMed PMID: 23949495.

81: Carella AM, Branford S, Deininger M, Mahon FX, Saglio G, Eiring A, Khorashad J, O'Hare T, Goldman JM. What challenges remain in chronic myeloid leukemia research? *Haematologica*. 2013 Aug;98(8):1168-72. doi: 10.3324/haematol.2013.090381. PubMed PMID: 23904234; PubMed Central PMCID: PMC3729896.

82: Bracco E, Rosso V, Serra A, Carnuccio F, Gaidano V, Nicoli P, Musto P, Saglio G, Frassoni F, Cilloni D. Design and application of a novel PNA probe for the

detection at single cell level of JAK2V617F mutation in Myeloproliferative Neoplasms. *BMC Cancer*. 2013 Jul 18;13:348. doi: 10.1186/1471-2407-13-348. PubMed PMID: 23865766; PubMed Central PMCID: PMC3728119.

83: Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousset P, Saglio G, Saúzele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. *Blood*. 2013 Aug 8;122(6):872-84. doi: 10.1182/blood-2013-05-501569. Review. PubMed PMID: 23803709; PubMed Central PMCID: PMC4915804.

84: Experts in Chronic Myeloid Leukemia.. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. *Blood*. 2013 May 30;121(22):4439-42. doi: 10.1182/blood-2013-03-490003. PubMed PMID: 23620577; PubMed Central PMCID: PMC4190613.

85: Stein AM, Martinelli G, Hughes TP, Müller MC, Beppu L, Gottardi E, Branford S, Soverini S, Woodman RC, Hochhaus A, Kim DW, Saglio G, Radich JP. Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia. *BMC Cancer*. 2013 Apr 2;13:173. doi: 10.1186/1471-2407-13-173. PubMed PMID: 23547655; PubMed Central PMCID: PMC3646679.

86: Hochhaus A, Saglio G, Larson RA, Kim DW, Etienne G, Rosti G, De Souza C, Kurokawa M, Kalaycio ME, Hoenekopp A, Fan X, Shou Y, Kantarjian HM, Hughes TP. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. *Blood*. 2013 May 2;121(18):3703-8. doi: 10.1182/blood-2012-04-423418. PubMed PMID: 23502220; PubMed Central PMCID: PMC4915803.

87: Giles FJ, Mauro MJ, Hong F, Ortmann CE, McNeill C, Woodman RC, Hochhaus A, le Coutre PD, Saglio G. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. *Leukemia*. 2013 Jun;27(6):1310-5. doi: 10.1038/leu.2013.69. PubMed PMID: 23459450.

88: Cilloni D, Carturan S, Bracco E, Campia V, Rosso V, Torti D, Calabrese C, Gaidano V, Niparuck P, Favole A, Signorino E, Iacobucci I, Morano A, De Luca L, Musto P, Frassoni F, Saglio G. Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia. *Leuk Res*. 2013 May;37(5):520-30. doi: 10.1016/j.leukres.2013.01.014. PubMed PMID: 23415111.

89: Blijlevens N, de Château M, Krivan G, Rabitsch W, Szomor A, Pytlik R, Lissmats A, Johnsen HE, de Witte T, Einsele H, Ruutu T, Niederwieser D; CLWP of the EBMT.. In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden. *Bone Marrow Transplant*. 2013 Jul;48(7):966-71. doi: 10.1038/bmt.2012.257. PubMed PMID: 23241739.

90: Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, Ruggeri M, Rumi E, Scortechini AR, Santini S, Scarano M, Siragusa S, Spadea A, Tieghi A, Angelucci E, Visani G, Vannucchi AM, Barbui T; CYTO-PV Collaborative Group.. Cardiovascular events and intensity of treatment in polycythemia vera. *N Engl J Med*. 2013 Jan 3;368(1):22-33. doi: 10.1056/NEJMoa1208500. PubMed PMID: 23216616.

91: Jabbour E, le Coutre PD, Cortes J, Giles F, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Hughes TP, Saglio G, Radich JP, Kim DW, Martinelli G, Reynolds J, Woodman RC, Baccarani M, Kantarjian HM. Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. *Leukemia*. 2013 Apr;27(4):907-13. doi: 10.1038/leu.2012.305. PubMed PMID: 23174881; PubMed Central PMCID: PMC4140185.

92: Van Etten RA, Mauro M, Radich JP, Goldman JM, Saglio G, Jamieson C, Soverini S, Gambacorti-Passerini C, Hehlmann R, Martinelli G, Perrotti D, Scadden DT, Skorski T, Tefferi A, Mughal TI. Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop. *Leuk Lymphoma*. 2013 Jun;54(6):1151-8. doi: 10.3109/10428194.2012.745524. Review. PubMed PMID: 23121619; PubMed Central PMCID: PMC3612371.

93: Branford S, Kim DW, Soverini S, Haque A, Shou Y, Woodman RC, Kantarjian HM, Martinelli G, Radich JP, Saglio G, Hochhaus A, Hughes TP, Müller MC. Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. *J Clin Oncol*. 2012 Dec 10;30(35):4323-9. doi: 10.1200/JCO.2011.40.5217. PubMed PMID: 23109697; PubMed Central PMCID: PMC4979159.

94: Angelini S, Soverini S, Ravegnini G, Barnett M, Turrini E, Thornquist M, Pane F, Hughes TP, White DL, Radich J, Kim DW, Saglio G, Cilloni D, Iacobucci I, Perini G, Woodman R, Cantelli-Forti G, Baccarani M, Hrelia P, Martinelli G. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. *Haematologica*. 2013 Feb;98(2):193-200. doi:

10.3324/haematol.2012.066480. PubMed PMID: 22875622; PubMed Central PMCID: PMC3561425.

95: Saglio G. Second-generation TKIs: which and when? *Leuk Suppl.* 2012 Aug;1(Suppl 2):S40-2. doi: 10.1038/leusup.2012.22. PubMed PMID: 27175246; PubMed Central PMCID: PMC4851203.

96: Fava C, Rege-Cambrin G, Saglio G. Chronic myeloid leukemia: state of the art in 2012. *Curr Oncol Rep.* 2012 Oct;14(5):379-86. doi: 10.1007/s11912-012-0253-9. Review. PubMed PMID: 22821153.

97: Pellegrino RM, Coutinho M, D'Ascola D, Lopes AM, Palmieri A, Carnuccio F, Costa M, Zecchina G, Saglio G, Costa E, Barbot J, Porto G, Pinto JP, Roetto A. Two novel mutations in the *tmprss6* gene associated with iron-refractory iron-deficiency anaemia (irida) and partial expression in the heterozygous form. *Br J Haematol.* 2012 Sep;158(5):668-72. doi: 10.1111/j.1365-2141.2012.09198.x. PubMed PMID: 22765023.

98: Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Novick S, Gillis K, Fan X, Cortes J, Baccarani M, Kantarjian HM. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. *Leukemia.* 2013 Jan;27(1):107-12. doi: 10.1038/leu.2012.181. PubMed PMID: 22763385.

99: Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW, Flinn IW, Kurokawa M, Moiraghi B, Yu R, Blakesley RE, Gallagher NJ, Saglio G, Kantarjian HM. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. *Leukemia.* 2012 Oct;26(10):2197-203. doi: 10.1038/leu.2012.134. PubMed PMID: 22699418.

100: Luatti S, Castagnetti F, Marzocchi G, Baldazzi C, Gugliotta G, Iacobucci I, Specchia G, Zanatta L, Rege-Cambrin G, Mancini M, Abruzzese E, Zaccaria A, Grimoldi MG, Gozzetti A, Ameli G, Capucci MA, Palka G, Bernasconi P, Palandri F, Pane F, Saglio G, Martinelli G, Rosti G, Baccarani M, Testoni N; Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Working Party on CML. Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. *Blood.* 2012 Jul 26;120(4):761-7. Erratum in: *Blood.* 2013 Jun 27;121(26):5259. Cambrin, Rege [corrected to Rege-Cambrin, Giovanna]. PubMed PMID: 22692507.

101: Jabbour E, Saglio G, Radich J, Kantarjian H. Adherence to BCR-ABL inhibitors: issues for CML therapy. *Clin Lymphoma Myeloma Leuk.* 2012

Aug;12(4):223-9. doi: 10.1016/j.clml.2012.04.002. Review. PubMed PMID: 22633166; PubMed Central PMCID: PMC4428159.

102: Yin OQ, Giles FJ, Baccarani M, le Coutre P, Chiparus O, Gallagher N, Saglio G, Hughes TP, Hochhaus A, Kantarjian HM, Larson RA. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. *Cancer Chemother Pharmacol.* 2012 Aug;70(2):345-50. doi: 10.1007/s00280-012-1881-3. PubMed PMID: 22623211.

103: Steegmann JL, Cervantes F, le Coutre P, Porkka K, Saglio G. Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. *Leuk Lymphoma.* 2012 Dec;53(12):2351-61. doi: 10.3109/10428194.2012.695779. Review. PubMed PMID: 22616642.

104: Guilhot J, Baccarani M, Clark RE, Cervantes F, Guilhot F, Hochhaus A, Kulikov S, Mayer J, Petzer AL, Rosti G, Rousselot P, Saglio G, Saussele S, Simonsson B, Steegmann JL, Zaritskey A, Hehlmann R. Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. *Blood.* 2012 Jun 21;119(25):5963-71. doi: 10.1182/blood-2011-10-383711. PubMed PMID: 22508936.

105: Cross NC, White HE, Müller MC, Saglio G, Hochhaus A. Standardized definitions of molecular response in chronic myeloid leukemia. *Leukemia.* 2012 Oct;26(10):2172-5. doi: 10.1038/leu.2012.104. Review. PubMed PMID: 22504141.

106: Casnici C, Volpe G, Crotta K, Lattuada D, Saglio G, Marelli O. Immunologic evaluation of peptides derived from BCR/ABL-out-of-frame fusion protein in HLA A2.1 transgenic mice. *J Immunother.* 2012 May;35(4):321-8. doi: 10.1097/CJI.0b013e3182562d37. PubMed PMID: 22495389.

107: Gale RP, Barosi G, Barbui T, Cervantes F, Dohner K, Dupriez B, Gupta V, Harrison C, Hoffman R, Kiladjian JJ, Mesa R, Mc Mullin MF, Passamonti F, Ribrag V, Roboz G, Saglio G, Vannucchi A, Verstovsek S. RBC-transfusion guidelines update. *Leuk Res.* 2012 May;36(5):659-60. doi: 10.1016/j.leukres.2012.01.023. PubMed PMID: 22336392.

108: Chiarella P, Summa V, De Santis S, Signori E, Picardi E, Pesole G, Saglio G, Fazio VM. BCR/ABL1 fusion transcripts generated from alternative splicing: implications for future targeted therapies in Ph+ leukaemias. *Curr Mol Med.* 2012 Jun;12(5):547-65. Review. PubMed PMID: 22300134.

109: White DL, Radich J, Soverini S, Saunders VA, Frede AK, Dang P, Cilloni D, Lin P, Mongay L, Woodman R, Manley P, Slader C, Kim DW, Pane F, Martinelli G,

Saglio G, Hughes TP. Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib. *Haematologica*. 2012 Jun;97(6):907-14. doi: 10.3324/haematol.2011.056457. PubMed PMID: 22207690; PubMed Central PMCID: PMC3366658.

110: Larson RA, Yin OQ, Hochhaus A, Saglio G, Clark RE, Nakamae H, Gallagher NJ, Demirhan E, Hughes TP, Kantarjian HM, le Coutre PD. Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. *Eur J Clin Pharmacol*. 2012 May;68(5):723-33. doi: 10.1007/s00228-011-1200-7. PubMed PMID: 22207416.

111: Cilloni D, Saglio G. Molecular pathways: BCR-ABL. *Clin Cancer Res*. 2012 Feb 15;18(4):930-7. doi: 10.1158/1078-0432.CCR-10-1613. Review. PubMed PMID: 22156549.

112: Jabbour E, Saglio G, Hughes TP, Kantarjian H. Suboptimal responses in chronic myeloid leukemia: implications and management strategies. *Cancer*. 2012 Mar 1;118(5):1181-91. doi: 10.1002/cncr.26391. Review. PubMed PMID: 22038681; PubMed Central PMCID: PMC3412948.

113: D'Avolio A, Simiele M, De Francia S, Ariaudo A, Baietto L, Cusato J, Fava C, Saglio G, Di Carlo F, Di Perri G. HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). *J Pharm Biomed Anal*. 2012 Feb 5;59:109-16. doi: 10.1016/j.jpba.2011.10.003. PubMed PMID: 22036594.

1: Mughal TI, Vannucchi AM, Soverini S, Bazeos A, Tibes R, Saglio G, Abdel-Wahab O, Pardanani A, Hehlmann R, Barbui T, Van Etten R, Tefferi A, Goldman JM. Current

pre-clinical and clinical advances in the BCR-ABL1-positive and -negative chronic myeloproliferative neoplasms. *Haematologica*. 2014 May;99(5):797-801. doi: 10.3324/haematol.2013.097832. PubMed PMID: 24790057; PubMed Central PMCID: PMC4008109.

2: Nai A, Pellegrino RM, Rausa M, Pagani A, Boero M, Silvestri L, Saglio G, Roetto A, Camaschella C. The erythroid function of Transferrin Receptor 2 revealed by Tmprss6 inactivation in different models of Transferrin Receptor 2 knock out mice. *Haematologica*. 2014 Mar 21. [Epub ahead of print] PubMed PMID: 24658816.

3: Shah NP, Guilhot F, Cortes JE, Schiffer CA, le Coutre P, Brümmendorf TH, Kantarjian HM, Hochhaus A, Rousselot P, Mohamed H, Healey D, Cunningham M, Saglio G. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study. *Blood*. 2014 Apr 10;123(15):2317-24. doi: 10.1182/blood-2013-10-532341. Epub 2014 Feb 25. PubMed PMID: 24569263.

4: Hughes TP, Hochhaus A, Kantarjian HM, Cervantes F, Guilhot F, Niederwieser D, le Coutre PD, Rosti G, Ossenkoppele G, Lobo C, Shibayama H, Fan X, Menssen HD, Kemp C, Larson RA, Saglio G. Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on frontline imatinib or nilotinib 300 mg twice daily. *Haematologica*. 2014 Feb 14. [Epub ahead of print] PubMed PMID: 24532039.

5: Breccia M, Alimena G, Baccarani M, Bocchia M, Di Raimondo F, Gambacorti-Passerini C, Gozzini A, Morra E, Pane F, Pregno P, Rege-Cambrin G, Rosti G, Specchia G, Vigneri P, Saglio G. Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013. *Crit Rev Oncol Hematol*. 2014 Jun;90(3):181-189. doi: 10.1016/j.critrevonc.2013.12.010. Epub 2013 Dec 17. Review. PubMed PMID: 24405858.

6: Morotti A, Panuzzo C, Fava C, Saglio G. Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia. *Expert Opin Biol Ther*. 2014 Mar;14(3):287-99. doi: 10.1517/14712598.2014.867323. Epub 2014 Jan 3. PubMed PMID: 24387320.

7: Barosi G, Vannucchi AM, De Stefano V, Pane F, Passamonti F, Rambaldi A, Saglio G, Barbui T, Tura S. Identifying and addressing unmet clinical needs in Ph-neg classical myeloproliferative neoplasms: a consensus-based SIE, SIES, GITMO position paper. *Leuk Res*. 2014 Feb;38(2):155-60. doi: 10.1016/j.leukres.2013.09.008. Epub 2013 Sep 19. PubMed PMID: 24378116.

8: De Francia S, D'Avolio A, Ariaudo A, Pirro E, Piccione F, Simiele M, Fava C,

Calcagno A, Di Perri G, Saglio G. Plasma and intracellular imatinib concentrations in patients with chronic myeloid leukemia. *Ther Drug Monit.* 2014 Jun;36(3):410-2. doi: 10.1097/FTD.000000000000013. PubMed PMID: 24342895.

9: Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G, Nakaseko C, De Souza CA, Kalaycio ME, Meier S, Fan X, Menssen HD, Larson RA, Hochhaus A. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. *Blood.* 2014 Feb 27;123(9):1353-60. doi: 10.1182/blood-2013-06-510396. Epub 2013 Dec 11. PubMed PMID: 24335106.

10: Morotti A, Panuzzo C, Crivellaro S, Pergolizzi B, Familiari U, Berger AH, Saglio G, Pandolfi PP. BCR-ABL disrupts PTEN nuclear-cytoplasmic shuttling through phosphorylation-dependent activation of HAUSP. *Leukemia.* 2013 Dec 9. doi: 10.1038/leu.2013.370. [Epub ahead of print] PubMed PMID: 24317448.

11: Jabbour E, Kantarjian HM, Saglio G, Steegmann JL, Shah NP, Boqué C, Chuah C, Pavlovsky C, Mayer J, Cortes J, Baccarani M, Kim DW, Bradley-Garelik MB, Mohamed H, Wildgust M, Hochhaus A. Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION). *Blood.* 2014 Jan 23;123(4):494-500. doi: 10.1182/blood-2013-06-511592. Epub 2013 Dec 5. PubMed PMID: 24311723.

12: Fava C, Rege-Cambrin G, Busca A, Gottardi E, Daraio F, Saglio G. Second-generation tyrosine kinase inhibitors can induce complete molecular response in Ph-positive acute lymphoblastic leukemia after allogeneic stem cell transplant. *Clin Lymphoma Myeloma Leuk.* 2013 Sep;13 Suppl 2:S272-5. doi: 10.1016/j.clml.2013.05.017. PubMed PMID: 24290212.

13: Quintarelli C, De Angelis B, Errichiello S, Caruso S, Esposito N, Colavita I, Raia M, Pagliuca S, Pugliese N, Risitano AM, Picardi M, Luciano L, Saglio G, Martinelli G, Pane F. Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia. *Leuk Res.* 2014 Feb;38(2):236-42. doi: 10.1016/j.leukres.2013.11.006. Epub 2013 Nov 15. PubMed PMID: 24280282.

14: Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H; PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. *N Engl J Med.* 2013 Nov 7;369(19):1783-96. doi: 10.1056/NEJMoa1306494. Epub 2013 Nov 1. PubMed PMID: 24180494; PubMed Central PMCID: PMC3886799.

15: Ladetto M, Lobetti-Bodoni C, Mantoan B, Ceccarelli M, Boccomini C, Genuardi E, Chiappella A, Baldini L, Rossi G, Pulsoni A, Di Raimondo F, Rigacci L, Pinto A, Galimberti S, Bari A, Rota-Scalabrini D, Ferrari A, Zaja F, Gallamini A, Specchia G, Musto P, Rossi FG, Gamba E, Evangelista A, Vitolo U; Fondazione Italiana Linfomi. Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. *Blood*. 2013 Nov 28;122(23):3759-66. doi: 10.1182/blood-2013-06-507319. Epub 2013 Oct 1. PubMed PMID: 24085766.

16: Savona MR, Saglio G. Identifying the time to change BCR-ABL inhibitor therapy in patients with chronic myeloid leukemia. *Acta Haematol*. 2013;130(4):268-78. doi: 10.1159/000353163. Epub 2013 Aug 15. Review. PubMed PMID: 23949495.

17: Carella AM, Branford S, Deininger M, Mahon FX, Saglio G, Eiring A, Khorashad J, O'Hare T, Goldman JM. What challenges remain in chronic myeloid leukemia research? *Haematologica*. 2013 Aug;98(8):1168-72. doi: 10.3324/haematol.2013.090381. PubMed PMID: 23904234; PubMed Central PMCID: PMC3729896.

18: Bracco E, Rosso V, Serra A, Carnuccio F, Gaidano V, Nicoli P, Musto P, Saglio G, Frassoni F, Cilloni D. Design and application of a novel PNA probe for the detection at single cell level of JAK2V617F mutation in Myeloproliferative Neoplasms. *BMC Cancer*. 2013 Jul 18;13:348. doi: 10.1186/1471-2407-13-348. PubMed PMID: 23865766; PubMed Central PMCID: PMC3728119.

19: Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Pane F, Radich JP, Rousselot P, Saglio G, Saúzele S, Schiffer C, Silver R, Simonsson B, Steegmann JL, Goldman JM, Hehlmann R. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. *Blood*. 2013 Aug 8;122(6):872-84. doi: 10.1182/blood-2013-05-501569. Epub 2013 Jun 26. Review. PubMed PMID: 23803709.

20: Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. *Blood*. 2013 May 30;121(22):4439-42. doi: 10.1182/blood-2013-03-490003. Epub 2013 Apr 25. PubMed PMID: 23620577.

21: Stein AM, Martinelli G, Hughes TP, Müller MC, Beppu L, Gottardi E, Branford S, Soverini S, Woodman RC, Hochhaus A, Kim DW, Saglio G, Radich JP. Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia. *BMC Cancer*.

2013 Apr 2;13(1):173. [Epub ahead of print] PubMed PMID: 23547655; PubMed Central PMCID: PMC3646679.

22: Hochhaus A, Saglio G, Larson RA, Kim DW, Etienne G, Rosti G, De Souza C, Kurokawa M, Kalaycio ME, Hoenekopp A, Fan X, Shou Y, Kantarjian HM, Hughes TP. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. *Blood*. 2013 May 2;121(18):3703-8. doi: 10.1182/blood-2012-04-423418. Epub 2013 Mar 15. PubMed PMID: 23502220.

23: Giles FJ, Mauro MJ, Hong F, Ortmann CE, McNeill C, Woodman RC, Hochhaus A, le Coutre PD, Saglio G. Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis. *Leukemia*. 2013 Jun;27(6):1310-5. doi: 10.1038/leu.2013.69. Epub 2013 Mar 5. PubMed PMID: 23459450.

24: Cilloni D, Carturan S, Bracco E, Campia V, Rosso V, Torti D, Calabrese C, Gaidano V, Niparuck P, Favole A, Signorino E, Iacobucci I, Morano A, De Luca L, Musto P, Frassoni F, Saglio G. Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia. *Leuk Res*. 2013 May;37(5):520-30. doi: 10.1016/j.leukres.2013.01.014. Epub 2013 Feb 12. PubMed PMID: 23415111.

25: Blijlevens N, de Chateau M, Krivan G, Rabitsch W, Szomor A, Pytlik R, Lissmats A, Johnsen HE, de Witte T, Einsele H, Ruutu T, Niederwieser D; CLWP of the EBMT. In a high-dose melphalan setting, palifermin compared with placebo had no effect on oral mucositis or related patient's burden. *Bone Marrow Transplant*. 2013 Jul;48(7):966-71. doi: 10.1038/bmt.2012.257. Epub 2012 Dec 17. PubMed PMID: 23241739.

26: Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, De Stefano V, Elli E, Iurlo A, Latagliata R, Lunghi F, Lunghi M, Marfisi RM, Musto P, Masciulli A, Musolino C, Cascavilla N, Quarta G, Randi ML, Rapezzi D, Ruggeri M, Rumi E, Scortechini AR, Santini S, Scarano M, Siragusa S, Spadea A, Tieghi A, Angelucci E, Visani G, Vannucchi AM, Barbui T; CYTO-PV Collaborative Group. Cardiovascular events and intensity of treatment in polycythemia vera. *N Engl J Med*. 2013 Jan 3;368(1):22-33. doi: 10.1056/NEJMoa1208500. Epub 2012 Dec 8. PubMed PMID: 23216616.

27: Jabbour E, le Coutre PD, Cortes J, Giles F, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Hughes TP, Saglio G, Radich JP, Kim DW, Martinelli G, Reynolds J, Woodman RC, Baccarani M, Kantarjian HM. Prediction of outcomes in patients with Ph⁺ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance. *Leukemia*.

2013 Apr;27(4):907-13. doi: 10.1038/leu.2012.305. Epub 2012 Nov 6. PubMed PMID: 23174881.

28: Van Etten RA, Mauro M, Radich JP, Goldman JM, Saglio G, Jamieson C, Soverini S, Gambacorti-Passerini C, Hehlmann R, Martinelli G, Perrotti D, Scadden DT, Skorski T, Tefferi A, Mughal TI. Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop. *Leuk Lymphoma*. 2013 Jun;54(6):1151-8. doi: 10.3109/10428194.2012.745524. Epub 2012 Dec 10. Review. PubMed PMID: 23121619; PubMed Central PMCID: PMC3612371.

29: Branford S, Kim DW, Soverini S, Haque A, Shou Y, Woodman RC, Kantarjian HM, Martinelli G, Radich JP, Saglio G, Hochhaus A, Hughes TP, Müller MC. Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. *J Clin Oncol*. 2012 Dec 10;30(35):4323-9. doi: 10.1200/JCO.2011.40.5217. Epub 2012 Oct 29. PubMed PMID: 23109697.

30: Angelini S, Soverini S, Ravegnini G, Barnett M, Turrini E, Thornquist M, Pane F, Hughes TP, White DL, Radich J, Kim DW, Saglio G, Cilloni D, Iacobucci I, Perini G, Woodman R, Cantelli-Forti G, Baccarani M, Hrelia P, Martinelli G. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. *Haematologica*. 2013 Feb;98(2):193-200. doi: 10.3324/haematol.2012.066480. Epub 2012 Aug 8. PubMed PMID: 22875622; PubMed Central PMCID: PMC3561425.

31: Fava C, Rege-Cambrin G, Saglio G. Chronic myeloid leukemia: state of the art in 2012. *Curr Oncol Rep*. 2012 Oct;14(5):379-86. doi: 10.1007/s11912-012-0253-9. Review. PubMed PMID: 22821153.

32: Pellegrino RM, Coutinho M, D'Ascola D, Lopes AM, Palmieri A, Carnuccio F, Costa M, Zecchina G, Saglio G, Costa E, Barbot J, Porto G, Pinto JP, Roetto A. Two novel mutations in the *tmprss6* gene associated with iron-refractory iron-deficiency anaemia (*irida*) and partial expression in the heterozygous form. *Br J Haematol*. 2012 Sep;158(5):668-72. doi: 10.1111/j.1365-2141.2012.09198.x. Epub 2012 Jul 5. PubMed PMID: 22765023.

33: Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Novick S, Gillis K, Fan X, Cortes J, Baccarani M, Kantarjian HM. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. *Leukemia*. 2013 Jan;27(1):107-12. doi: 10.1038/leu.2012.181. Epub 2012 Jul 5. PubMed PMID:

22763385.

34: Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW, Flinn IW, Kurokawa M, Moiraghi B, Yu R, Blakesley RE, Gallagher NJ, Saglio G, Kantarjian HM. Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. *Leukemia*. 2012 Oct;26(10):2197-203. doi: 10.1038/leu.2012.134. Epub 2012 May 18. PubMed PMID: 22699418.

35: Luatti S, Castagnetti F, Marzocchi G, Baldazzi C, Gugliotta G, Iacobucci I, Specchia G, Zanatta L, Rege-Cambrin G, Mancini M, Abruzzese E, Zaccaria A, Grimoldi MG, Gozzetti A, Ameli G, Capucci MA, Palka G, Bernasconi P, Palandri F, Pane F, Saglio G, Martinelli G, Rosti G, Baccarani M, Testoni N; Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Working Party on CML. Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis. *Blood*. 2012 Jul 26;120(4):761-7. Epub 2012 Jun 12. Erratum in: *Blood*. 2013 Jun 27;121(26):5259. Cambrin, Rege [corrected to Rege-Cambrin, Giovanna]. PubMed PMID: 22692507.

36: Jabbour E, Saglio G, Radich J, Kantarjian H. Adherence to BCR-ABL inhibitors: issues for CML therapy. *Clin Lymphoma Myeloma Leuk*. 2012 Aug;12(4):223-9. doi: 10.1016/j.clml.2012.04.002. Epub 2012 May 24. Review. PubMed PMID: 22633166.

37: Yin OQ, Giles FJ, Baccarani M, le Coutre P, Chiparus O, Gallagher N, Saglio G, Hughes TP, Hochhaus A, Kantarjian HM, Larson RA. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. *Cancer Chemother Pharmacol*. 2012 Aug;70(2):345-50. doi: 10.1007/s00280-012-1881-3. Epub 2012 May 24. PubMed PMID: 22623211.

38: Steegmann JL, Cervantes F, le Coutre P, Porkka K, Saglio G. Off-target effects of BCR-ABL1 inhibitors and their potential long-term implications in patients with chronic myeloid leukemia. *Leuk Lymphoma*. 2012 Dec;53(12):2351-61. doi: 10.3109/10428194.2012.695779. Epub 2012 Jun 18. Review. PubMed PMID: 22616642.

39: Guilhot J, Baccarani M, Clark RE, Cervantes F, Guilhot F, Hochhaus A, Kulikov S, Mayer J, Petzer AL, Rosti G, Rousselot P, Saglio G, Saussele S, Simonsson B, Steegmann JL, Zariwsky A, Hehlmann R. Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet. *Blood*. 2012 Jun 21;119(25):5963-71. doi: 10.1182/blood-2011-10-383711. Epub 2012 Apr 16. PubMed PMID: 22508936.

40: Cross NC, White HE, Müller MC, Saglio G, Hochhaus A. Standardized definitions

of molecular response in chronic myeloid leukemia. *Leukemia*. 2012 Oct;26(10):2172-5. doi: 10.1038/leu.2012.104. Epub 2012 Apr 16. Review. PubMed PMID: 22504141.

41: Casnici C, Volpe G, Crotta K, Lattuada D, Saglio G, Marelli O. Immunologic evaluation of peptides derived from BCR/ABL-out-of-frame fusion protein in HLA A2.1 transgenic mice. *J Immunother*. 2012 May;35(4):321-8. doi: 10.1097/CJI.0b013e3182562d37. PubMed PMID: 22495389.

42: Gale RP, Barosi G, Barbui T, Cervantes F, Dohner K, Dupriez B, Gupta V, Harrison C, Hoffman R, Kiladjian JJ, Mesa R, Mc Mullin MF, Passamonti F, Ribrag V, Roboz G, Saglio G, Vannucchi A, Verstovsek S. RBC-transfusion guidelines update. *Leuk Res*. 2012 May;36(5):659-60. doi: 10.1016/j.leukres.2012.01.023. Epub 2012 Feb 14. PubMed PMID: 22336392.

43: Chiarella P, Summa V, De Santis S, Signori E, Picardi E, Pesole G, Saglio G, Fazio VM. BCR/ABL1 fusion transcripts generated from alternative splicing: implications for future targeted therapies in Ph+ leukaemias. *Curr Mol Med*. 2012 Jun;12(5):547-65. Review. PubMed PMID: 22300134.

44: Saglio G, Fava C. Practical monitoring of chronic myelogenous leukemia: when to change treatment. *J Natl Compr Canc Netw*. 2012 Jan;10(1):121-9. Review. PubMed PMID: 22223872.

45: White DL, Radich J, Soverini S, Saunders VA, Frede AK, Dang P, Cilloni D, Lin P, Mongay L, Woodman R, Manley P, Slader C, Kim DW, Pane F, Martinelli G, Saglio G, Hughes TP. Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib. *Haematologica*. 2012 Jun;97(6):907-14. doi: 10.3324/haematol.2011.056457. Epub 2011 Dec 29. PubMed PMID: 22207690; PubMed Central PMCID: PMC3366658.

46: Larson RA, Yin OQ, Hochhaus A, Saglio G, Clark RE, Nakamae H, Gallagher NJ, Demirhan E, Hughes TP, Kantarjian HM, le Coutre PD. Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. *Eur J Clin Pharmacol*. 2012 May;68(5):723-33. doi: 10.1007/s00228-011-1200-7. Epub 2011 Dec 30. PubMed PMID: 22207416.

47: Cilloni D, Saglio G. Molecular pathways: BCR-ABL. *Clin Cancer Res*. 2012 Feb 15;18(4):930-7. doi: 10.1158/1078-0432.CCR-10-1613. Epub 2011 Dec 8. Review. PubMed PMID: 22156549.

48: Pirro E, De Francia S, De Martino F, Fava C, Ulisciani S, Cambrin GR, Racca S, Saglio G, Di Carlo F. A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients. *J Chromatogr Sci*. 2011 Nov-Dec;49(10):753-7. PubMed PMID: 22080802.

49: Jabbour E, Saglio G, Hughes TP, Kantarjian H. Suboptimal responses in chronic myeloid leukemia: implications and management strategies. *Cancer*. 2012 Mar 1;118(5):1181-91. doi: 10.1002/cncr.26391. Epub 2011 Oct 28. Review. PubMed PMID: 22038681; PubMed Central PMCID: PMC3412948.

50: D'Avolio A, Simiele M, De Francia S, Ariaudo A, Baietto L, Cusato J, Fava C, Saglio G, Di Carlo F, Di Perri G. HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC). *J Pharm Biomed Anal*. 2012 Feb 5;59:109-16. doi: 10.1016/j.jpba.2011.10.003. Epub 2011 Oct 14. PubMed PMID: 22036594.

51: Nicolini FE, Basak GW, Soverini S, Martinelli G, Mauro MJ, Müller MC, Hochhaus A, Chuah C, Dufva IH, Rege-Cambrin G, Saglio G, Michallet M, Labussière H, Morisset S, Hayette S, Etienne G, Olavarria E, Zhou W, Peter S, Apperley JF, Cortes J. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. *Blood*. 2011 Nov 17;118(20):5697-700. doi: 10.1182/blood-2011-07-367326. Epub 2011 Sep 16. PubMed PMID: 21926354.

52: Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, Goh YT, Rosti G, Nakamae H, Gallagher NJ, Hoenekopp A, Blakesley RE, Larson RA, Hughes TP. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. *Lancet Oncol*. 2011 Sep;12(9):841-51. doi: 10.1016/S1470-2045(11)70201-7. Epub 2011 Aug 17. Erratum in: *Lancet Oncol*. 2011 Oct;12(11):989. PubMed PMID: 21856226.

53: Esposito N, Colavita I, Quintarelli C, Sica AR, Peluso AL, Luciano L, Picardi M, Del Vecchio L, Buonomo T, Hughes TP, White D, Radich JP, Russo D, Branford S, Saglio G, Melo JV, Martinelli R, Ruoppolo M, Kalebic T, Martinelli G, Pane F. SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia. *Blood*. 2011 Sep 29;118(13):3634-44. doi: 10.1182/blood-2011-03-341073. Epub 2011 Aug 5. PubMed PMID: 21821701.

54: Efficace F, Baccarani M, Breccia M, Alimena G, Rosti G, Cottone F, Deliliers GL, Baratè C, Rossi AR, Fioritoni G, Luciano L, Turri D, Martino B, Di Raimondo F, Dabusti M, Bergamaschi M, Leoni P, Simula MP, Levato L, Ulisciani S, Veneri D, Sica S, Rambaldi A, Vignetti M, Mandelli F; GIMEMA. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with

imatinib compared with the general population. *Blood*. 2011 Oct 27;118(17):4554-60. doi: 10.1182/blood-2011-04-347575. Epub 2011 Jul 12. PubMed PMID: 21750313.

55: Falco P, Levis A, Stacchini A, Ciriello MM, Geuna M, Notari P, Omedè P, Pautasso M, Prato G, Strola G, Gioia D, Bonferroni M, Cametti G, Ferrero D, Freilone R, Gaidano G, Marinone C, Marmont F, Pollio B, Salvi F, Saglio G, Giroto M; Piedmont MDS Registry--Italy. Prognostic relevance of cytometric quantitative assessment in patients with myelodysplastic syndromes. *Eur J Haematol*. 2011 Nov;87(5):409-18. doi: 10.1111/j.1600-0609.2011.01676.x. Epub 2011 Aug 11. PubMed PMID: 21711395.

56: Casnici C, Volpe G, Crotta K, Panuzzo C, Lattuada D, Cabras CA, Longhi R, Saglio G, Marelli O. Characterization of a monoclonal antibody specific for novel Bcr/Abl out-of-frame fusion proteins. *Hybridoma (Larchmt)*. 2011 Jun;30(3):261-9. doi: 10.1089/hyb.2010.0122. PubMed PMID: 21707361.

57: Porter JB, Lin KH, Beris P, Forni GL, Taher A, Habr D, Domokos G, Roubert B, Thein SL; EPIC study investigators. Response of iron overload to deferasirox in rare transfusion-dependent anaemias: equivalent effects on serum ferritin and labile plasma iron for haemolytic or production anaemias. *Eur J Haematol*. 2011 Oct;87(4):338-48. doi: 10.1111/j.1600-0609.2011.01660.x. Epub 2011 Jul 29. PubMed PMID: 21649735; PubMed Central PMCID: PMC3229702.

58: Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, Pane F, Müller MC, Ernst T, Rosti G, Porkka K, Baccharani M, Cross NC, Martinelli G. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. *Blood*. 2011 Aug 4;118(5):1208-15. doi: 10.1182/blood-2010-12-326405. Epub 2011 May 11. Review. PubMed PMID: 21562040.

59: Jabbour E, Branford S, Saglio G, Jones D, Cortes JE, Kantarjian HM. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. *Cancer*. 2011 May 1;117(9):1800-11. doi: 10.1002/cncr.25717. Epub 2010 Nov 29. Review. Erratum in: *Cancer*. 2011 Aug;117(15):3535. PubMed PMID: 21509757.

60: Gugliotta G, Castagnetti F, Palandri F, Breccia M, Intermesoli T, Capucci A, Martino B, Pregno P, Rupoli S, Ferrero D, Gherlinzoni F, Montefusco E, Bocchia M, Tiribelli M, Pierri I, Grifoni F, Marzocchi G, Amabile M, Testoni N, Martinelli G, Alimena G, Pane F, Saglio G, Baccharani M, Rosti G; Gruppo Italiano Malattie Ematologiche dell'Adulto CML Working Party. Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. *Blood*. 2011 May 26;117(21):5591-9. doi: 10.1182/blood-2010-12-324228. Epub 2011 Mar 30. PubMed PMID: 21450900.

61: Marzocchi G, Castagnetti F, Luatti S, Baldazzi C, Stacchini M, Gugliotta G, Amabile M, Specchia G, Sessarego M, Giussani U, Valori L, Discepoli G, Montaldi A, Santoro A, Bonaldi L, Giudici G, Cianciulli AM, Giacobbi F, Palandri F, Pane F, Saglio G, Martinelli G, Baccarani M, Rosti G, Testoni N; Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA) Working Party on Chronic Myeloid Leukemia. Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. *Blood*. 2011 Jun 23;117(25):6793-800. doi: 10.1182/blood-2011-01-328294. Epub 2011 Mar 29. PubMed PMID: 21447834.

62: Goh HG, Lin M, Fukushima T, Saglio G, Kim D, Choi SY, Kim SH, Lee J, Lee YS, Oh SM, Kim DW. Sensitive quantitation of minimal residual disease in chronic myeloid leukemia using nanofluidic digital polymerase chain reaction assay. *Leuk Lymphoma*. 2011 May;52(5):896-904. doi: 10.3109/10428194.2011.555569. Epub 2011 Feb 21. PubMed PMID: 21338281.

63: Guglielmelli T, Brinchen S, Rrodhe S, Gay F, Cavallo F, Berruti A, Montefusco V, Piro E, Benevolo G, Petrucci MT, Caravita T, Offidani M, Corradini P, Boccadoro M, Saglio G, Palumbo A. Previous thalidomide therapy may not affect lenalidomide response and outcome in relapse or refractory multiple myeloma patients. *Eur J Cancer*. 2011 Apr;47(6):814-8. doi: 10.1016/j.ejca.2010.12.026. Epub 2011 Feb 18. PubMed PMID: 21334196.

64: Kantarjian HM, Baccarani M, Jabbour E, Saglio G, Cortes JE. Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy. *Clin Cancer Res*. 2011 Apr 1;17(7):1674-83. doi: 10.1158/1078-0432.CCR-10-2922. Epub 2011 Feb 9. Review. PubMed PMID: 21307148.

65: Saglio G, Kantarjian H, Holyoake T, Ranganathan A, Cortés JE; Panel at the Third Global Workshop on Chronic Myeloid Leukemia. Proceedings of the Third Global Workshop on Chronic Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk*. 2010 Dec;10(6):443-51. doi: 10.3816/CLML.2010.n.077. Review. PubMed PMID: 21156461.

66: Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Shou Y, Gallagher NJ, Blakesley R, Baccarani M, Cortes J, le Coutre PD. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. *Blood*. 2011 Jan 27;117(4):1141-5. doi: 10.1182/blood-2010-03-277152. Epub 2010 Nov 22. PubMed PMID: 21098399.

67: Giles FJ, Rosti G, Beris P, Clark RE, le Coutre P, Mahon FX, Steegmann JL, Valent P, Saglio G. Nilotinib is superior to imatinib as first-line therapy of

chronic myeloid leukemia: the ENESTnd study. *Expert Rev Hematol*. 2010 Dec;3(6):665-73. doi: 10.1586/ehm.10.61. Epub 2010 Nov 9. PubMed PMID: 21091142.

68: Guglielmelli T, Petrucci MT, Saglio G, Palumbo A. Thalidomide after lenalidomide: a possible treatment regimen in relapse refractory multiple myeloma patients. *Br J Haematol*. 2011 Jan;152(1):108-10. doi: 10.1111/j.1365-2141.2010.08416.x. Epub 2010 Nov 18. Erratum in: *Br J Haematol*. 2011 Apr;153(1):146. PubMed PMID: 21083653.

69: Alimena G, Breccia M, Musto P, Cilloni D, D'Auria F, Latagliata R, Sanpaolo G, Gottardi E, Saglio G, Mandelli F. Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes. *Leuk Res*. 2011 Apr;35(4):504-7. doi: 10.1016/j.leukres.2010.08.021. Epub 2010 Oct 23. PubMed PMID: 20971509.

70: La Starza R, Matteucci C, Gorello P, Brandimarte L, Pierini V, Crescenzi B, Nofrini V, Rosati R, Gottardi E, Saglio G, Santucci A, Berchicci L, Arcioni F, Falini B, Martelli MF, Sambani C, Aventin A, Mecucci C. NPM1 deletion is associated with gross chromosomal rearrangements in leukemia. *PLoS One*. 2010 Sep 21;5(9):e12855. doi: 10.1371/journal.pone.0012855. PubMed PMID: 20877721; PubMed Central PMCID: PMC2943467.

71: Fava C, Saglio G. Can we and should we improve on frontline imatinib therapy for chronic myeloid leukemia? *Semin Hematol*. 2010 Oct;47(4):319-26. doi: 10.1053/j.seminhematol.2010.06.001. Review. PubMed PMID: 20875548.

72: Cilloni D, Frassoni F, Saglio G. Emerging targets for hematological malignancies. *Curr Opin Drug Discov Devel*. 2010 Sep;13(5):548-58. Review. PubMed PMID: 20812146.

73: White HE, Matejtschuk P, Rigsby P, Gabert J, Lin F, Lynn Wang Y, Branford S, Müller MC, Beaufils N, Beillard E, Colomer D, Dvorakova D, Ehrencrona H, Goh HG, El Housni H, Jones D, Kairisto V, Kamel-Reid S, Kim DW, Langabeer S, Ma ES, Press RD, Romeo G, Wang L, Zoi K, Hughes T, Saglio G, Hochhaus A, Goldman JM, Metcalfe P, Cross NC. Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. *Blood*. 2010 Nov 25;116(22):e111-7. doi: 10.1182/blood-2010-06-291641. Epub 2010 Aug 18. PubMed PMID: 20720184.

74: Gale RP, Barosi G, Barbui T, Cervantes F, Dohner K, Dupriez B, Gupta V, Harrison C, Hoffman R, Kiladjian JJ, Mesa R, Mc Mullin MF, Passamonti F, Ribrag V, Roboz G, Saglio G, Vannucchi A, Verstovsek S. What are RBC-transfusion-dependence and -independence? *Leuk Res*. 2011 Jan;35(1):8-11. doi: 10.1016/j.leukres.2010.07.015. Epub 2010 Aug 7. PubMed PMID: 20692036.

75: Messa E, Cilloni D, Saglio G. Iron chelation therapy in myelodysplastic syndromes. *Adv Hematol.* 2010;2010:756289. doi: 10.1155/2010/756289. Epub 2010 Jun 20. PubMed PMID: 20672005; PubMed Central PMCID: PMC2905902.

76: Lee JW, Yoon SS, Shen ZX, Ganser A, Hsu HC, Habr D, Domokos G, Roubert B, Porter JB; EPIC study investigators. Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. *Blood.* 2010 Oct 7;116(14):2448-54. doi: 10.1182/blood-2010-01-261289. Epub 2010 Jun 21. PubMed PMID: 20566896.

77: Saglio G, Hochhaus A, Goh YT, Masszi T, Pasquini R, Maloisel F, Erben P, Cortes J, Paquette R, Bradley-Garelik MB, Zhu C, Dombret H. Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily. *Cancer.* 2010 Aug 15;116(16):3852-61. doi: 10.1002/cncr.25123. PubMed PMID: 20564086.

78: Messa E, Carturan S, Maffè C, Pautasso M, Bracco E, Roetto A, Messa F, Arruga F, Defilippi I, Rosso V, Zanone C, Rotolo A, Greco E, Pellegrino RM, Alberti D, Saglio G, Cilloni D. Deferasirox is a powerful NF-kappaB inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging. *Haematologica.* 2010 Aug;95(8):1308-16. doi: 10.3324/haematol.2009.016824. Epub 2010 Jun 9. PubMed PMID: 20534700; PubMed Central PMCID: PMC2913079.

79: Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM; ENESTnd Investigators. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. *N Engl J Med.* 2010 Jun 17;362(24):2251-9. doi: 10.1056/NEJMoa0912614. Epub 2010 Jun 5. PubMed PMID: 20525993.

80: Saglio G, Baccarani M. First-line therapy for chronic myeloid leukemia: new horizons and an update. *Clin Lymphoma Myeloma Leuk.* 2010 Jun;10(3):169-76. doi: 10.3816/CLML.2010.n.026. Review. PubMed PMID: 20511160.

81: Saglio G. The best frontline therapy for CML: imatinib? *Clin Adv Hematol Oncol.* 2010 Apr;8(4):240-2. PubMed PMID: 20505646.

82: Gorin NC, Labopin M, Reiffers J, Milpied N, Blaise D, Witz F, de Witte T, Meloni G, Attal M, Bernal T, Rocha V; Acute Leukemia Working Party, European Cooperative Group for Blood and Marrow Transplantation. Higher incidence of

relapse in patients with acute myelocytic leukemia infused with higher doses of CD34+ cells from leukapheresis products autografted during the first remission. *Blood*. 2010 Oct 28;116(17):3157-62. doi: 10.1182/blood-2009-11-252197. Epub 2010 May 17. PubMed PMID: 20479285.

83: Gattermann N, Finelli C, Porta MD, Fenaux P, Ganser A, Guerci-Bresler A, Schmid M, Taylor K, Vassilieff D, Habr D, Domokos G, Roubert B, Rose C; EPIC study investigators. Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study. *Leuk Res*. 2010 Sep;34(9):1143-50. doi: 10.1016/j.leukres.2010.03.009. Epub 2010 May 6. PubMed PMID: 20451251.

84: Castagnetti F, Testoni N, Luatti S, Marzocchi G, Mancini M, Kerim S, Giugliano E, Albano F, Cuneo A, Abruzzese E, Martino B, Palandri F, Amabile M, Iacobucci I, Alimena G, Pane F, Martinelli G, Saglio G, Baccarani M, Rosti G. Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis. *J Clin Oncol*. 2010 Jun 1;28(16):2748-54. doi: 10.1200/JCO.2009.26.7963. Epub 2010 May 3. PubMed PMID: 20439635.

85: Cilloni D, Carturan S, Maffè C, Messa F, Arruga F, Messa E, Pradotto M, Pautasso M, Zanone C, Fornaciari P, Defilippi I, Rotolo A, Greco E, Iacobucci I, Martinelli G, Lo-Coco F, Bracco E, Saglio G. Proteinase 3 (PR3) gene is highly expressed in CBF leukemias and codes for a protein with abnormal nuclear localization that confers drug sensitivity. *Leukemia*. 2010 Apr 8. [Epub ahead of print] PubMed PMID: 20376087.

86: Palandri F, Castagnetti F, Iacobucci I, Martinelli G, Amabile M, Gugliotta G, Poerio A, Testoni N, Breccia M, Bocchia M, Crugnola M, Rege-Cambrin G, Martino B, Pierri I, Radaelli F, Specchia G, Pane F, Saglio G, Rosti G, Baccarani M. The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. *Haematologica*. 2010 Aug;95(8):1415-9. doi: 10.3324/haematol.2009.021246. Epub 2010 Mar 19. PubMed PMID: 20305139; PubMed Central PMCID: PMC2913092.

87: Cilloni D, Messa E, Rotolo A, Saglio G. Emerging drugs for chronic myeloid leukemia. *Expert Opin Emerg Drugs*. 2010 Jun;15(2):175-84. doi: 10.1517/14728211003621220. Review. PubMed PMID: 20201747.

88: Roetto A, Di Cunto F, Pellegrino RM, Hirsch E, Azzolino O, Bondi A, Defilippi I, Carturan S, Miniscalco B, Riondato F, Cilloni D, Silengo L, Altruda F, Camaschella C, Saglio G. Comparison of 3 Tfr2-deficient murine models suggests distinct functions for Tfr2-alpha and Tfr2-beta isoforms in different tissues.

Blood. 2010 Apr 22;115(16):3382-9. doi: 10.1182/blood-2009-09-240960. Epub 2010 Feb 23. PubMed PMID: 20179178.

89: Cilloni D, Carturan S, Maffè C, Messa F, Arruga F, Messa E, Pradotto M, Pautasso M, Zanone C, Fornaciari P, Defilippi I, Rotolo A, Greco E, Iacobucci I, Martinelli G, Lo-Coco F, Bracco E, Saglio G. WITHDRAWN: Proteinase 3 (PR3) gene is highly expressed in CBF leukemias and codes for a protein with abnormal nuclear localization that confers drug sensitivity. *Leukemia*. 2010 Jan 14. [Epub ahead of print] PubMed PMID: 20072158.

90: Guglielmelli T, Merlini R, Giugliano E, Saglio G. Lenalidomide, melphalan, and prednisone association is an effective salvage therapy in relapsed plasma cell leukaemia. *J Oncol*. 2009;2009:867380. doi: 10.1155/2009/867380. Epub . PubMed PMID: 20011654; PubMed Central PMCID: PMC2786165.

91: Pellicano F, Cilloni D, Helgason GV, Messa F, Panuzzo C, Arruga F, Bracco E, Allan E, Huntly BJ, Holyoake TL, Saglio G. FOXO transcription factor activity is partially retained in quiescent CML stem cells and induced by tyrosine kinase inhibitors in CML progenitor cells. *Blood*. 2009 Dec 1. doi: 10.1182/blood-2009-06-226621. Epub 2009 Dec 1. Retraction in: *Blood*. 2010 Apr 8;115(14):2983. PubMed PMID: 19965658.

92: Cilloni D, Saglio G. CML: a model for targeted therapy. *Best Pract Res Clin Haematol*. 2009 Sep;22(3):285-94. doi: 10.1016/j.beha.2009.04.004. Review. PubMed PMID: 19959080.

93: Messa E, Pellegrino RM, Palmieri A, Carturan S, Cilloni D, Saglio G, Roetto A. Identification of a novel mutation in the L ferritin iron-responsive element causing hereditary hyperferritinemia-cataract syndrome. *Acta Haematol*. 2009;122(4):223-5. doi: 10.1159/000253031. Epub 2009 Oct 29. PubMed PMID: 19887780.

94: Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R; European LeukemiaNet. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. *J Clin Oncol*. 2009 Dec 10;27(35):6041-51. doi: 10.1200/JCO.2009.25.0779. Epub 2009 Nov 2. Review. PubMed PMID: 19884523.

95: Rosti G, Palandri F, Castagnetti F, Breccia M, Levato L, Gugliotta G, Capucci A, Cedrone M, Fava C, Intermesoli T, Cambrin GR, Stagno F, Tiribelli M, Amabile M, Luatti S, Poerio A, Soverini S, Testoni N, Martinelli G, Alimena G, Pane F, Saglio G, Baccarani M; GIMEMA CML Working Party. Nilotinib for the frontline

treatment of Ph(+) chronic myeloid leukemia. *Blood*. 2009 Dec 3;114(24):4933-8. doi: 10.1182/blood-2009-07-232595. Epub 2009 Oct 12. PubMed PMID: 19822896.

96: Martinelli G, Iacobucci I, Storlazzi CT, Vignetti M, Paoloni F, Cilloni D, Soverini S, Vitale A, Chiaretti S, Cimino G, Papayannidis C, Paolini S, Elia L, Fazi P, Meloni G, Amadori S, Saglio G, Pane F, Baccarani M, Foà R. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report. *J Clin Oncol*. 2009 Nov 1;27(31):5202-7. doi: 10.1200/JCO.2008.21.6408. Epub 2009 Sep 21. PubMed PMID: 19770381.

97: Iacobucci I, Lonetti A, Messa F, Ferrari A, Cilloni D, Soverini S, Paoloni F, Arruga F, Ottaviani E, Chiaretti S, Messina M, Vignetti M, Papayannidis C, Vitale A, Pane F, Piccaluga PP, Paolini S, Berton G, Baruzzi A, Saglio G, Baccarani M, Foà R, Martinelli G. Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR-ABL1-positive acute lymphoblastic leukemia patients. *Leukemia*. 2010 Jan;24(1):66-73. doi: 10.1038/leu.2009.197. Epub 2009 Sep 17. PubMed PMID: 19759560.

98: Saglio G, Fava C. Inhibition of stromal cell-derived factor-1/CXCR4 axis for the cure of BCR-ABL positive chronic myeloid leukemia. *Leuk Lymphoma*. 2009 Oct;50(10):1564-5. doi: 10.1080/10428190903216853. PubMed PMID: 19757319.

99: Nicoli P, Familiari U, Bosa M, Alice T, Mete F, Morotti A, Cilloni D, Saglio G, Guerrasio A. HHV8-positive, HIV-negative multicentric Castleman's disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma. *Int J Hematol*. 2009 Oct;90(3):392-6. doi: 10.1007/s12185-009-0418-y. Epub 2009 Sep 12. PubMed PMID: 19756920.

100: Cilloni D, Renneville A, Hermitte F, Hills RK, Daly S, Jovanovic JV, Gottardi E, Fava M, Schnittger S, Weiss T, Izzo B, Nomdedeu J, van der Heijden A, van der Reijden BA, Jansen JH, van der Velden VH, Ommen H, Preudhomme C, Saglio G, Grimwade D. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. *J Clin Oncol*. 2009 Nov 1;27(31):5195-201. doi: 10.1200/JCO.2009.22.4865. Epub 2009 Sep 14. PubMed PMID: 19752335.

101: Müller MC, Cross NC, Erben P, Schenk T, Hanfstein B, Ernst T, Hehlmann R, Branford S, Saglio G, Hochhaus A. Harmonization of molecular monitoring of CML therapy in Europe. *Leukemia*. 2009 Nov;23(11):1957-63. doi: 10.1038/leu.2009.168. Epub 2009 Aug 27. Review. PubMed PMID: 19710700.

102: Hughes T, Saglio G, Branford S, Soverini S, Kim DW, Müller MC, Martinelli G,

Cortes J, Beppu L, Gottardi E, Kim D, Erben P, Shou Y, Haque A, Gallagher N, Radich J, Hochhaus A. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. *J Clin Oncol*. 2009 Sep 1;27(25):4204-10. doi: 10.1200/JCO.2009.21.8230. Epub 2009 Aug 3. PubMed PMID: 19652056.

103: Iacobucci I, Storlazzi CT, Cilloni D, Lonetti A, Ottaviani E, Soverini S, Astolfi A, Chiaretti S, Vitale A, Messa F, Impera L, Baldazzi C, D'Addabbo P, Papayannidis C, Lonoce A, Colarossi S, Vignetti M, Piccaluga PP, Paolini S, Russo D, Pane F, Saglio G, Baccarani M, Foà R, Martinelli G. Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute Leukemia Working Party (GIMEMA AL WP). *Blood*. 2009 Sep 3;114(10):2159-67. doi: 10.1182/blood-2008-08-173963. Epub 2009 Jul 9. Erratum in: *Blood*. 2010 Sep 23;116(12):2196. PubMed PMID: 19589926.

104: De Francia S, D'Avolio A, De Martino F, Pirro E, Baietto L, Siccardi M, Simiele M, Racca S, Saglio G, Di Carlo F, Di Perri G. New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2009 Jun 15;877(18-19):1721-6. doi: 10.1016/j.jchromb.2009.04.028. Epub 2009 Apr 24. PubMed PMID: 19428316.

105: Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Müller MC, Radich JP, Rudoltz M, Mone M, Gathmann I, Hughes TP, Larson RA; IRIS Investigators. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. *Leukemia*. 2009 Jun;23(6):1054-61. doi: 10.1038/leu.2009.38. Epub 2009 Mar 12. Erratum in: *Leukemia*. 2010 May;24(5):1102. PubMed PMID: 19282833.

106: Baccarani M, Rosti G, Castagnetti F, Haznedaroglu I, Porkka K, Abruzzese E, Alimena G, Ehrencrona H, Hjorth-Hansen H, Kairisto V, Levato L, Martinelli G, Nagler A, Lanng Nielsen J, Ozbek U, Palandri F, Palmieri F, Pane F, Rege-Cambrin G, Russo D, Specchia G, Testoni N, Weiss-Bjerrum O, Saglio G, Simonsson B. Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study. *Blood*. 2009 May 7;113(19):4497-504. doi: 10.1182/blood-2008-12-191254. Epub 2009 Mar 4. PubMed PMID: 19264678.

107: Castagnetti F, Palandri F, Amabile M, Testoni N, Luatti S, Soverini S, Iacobucci I, Breccia M, Rege Cambrin G, Stagno F, Specchia G, Galieni P, Iuliano F, Pane F, Saglio G, Alimena G, Martinelli G, Baccarani M, Rosti G; GIMEMA CML Working Party. Results of high-dose imatinib mesylate in intermediate Sokal risk chronic myeloid leukemia patients in early chronic phase: a phase 2 trial of the GIMEMA CML Working Party. *Blood*. 2009 Apr 9;113(15):3428-34. doi:

10.1182/blood-2007-08-103499. Epub 2009 Feb 11. PubMed PMID: 19211938.

108: Palandri F, Iacobucci I, Soverini S, Castagnetti F, Poerio A, Testoni N, Alimena G, Breccia M, Rege-Cambrin G, Tiribelli M, Varaldo R, Abruzzese E, Martino B, Luciano L, Pane F, Saglio G, Martinelli G, Baccarani M, Rosti G. Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response. *Clin Cancer Res.* 2009 Feb 1;15(3):1059-63. doi: 10.1158/1078-0432.CCR-08-1195. PubMed PMID: 19188180.

109: Palandri F, Castagnetti F, Alimena G, Testoni N, Breccia M, Luatti S, Rege-Cambrin G, Stagno F, Specchia G, Martino B, Levato L, Merante S, Liberati AM, Pane F, Saglio G, Alberti D, Martinelli G, Baccarani M, Rosti G. The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. *Haematologica.* 2009 Feb;94(2):205-12. doi: 10.3324/haematol.13529. Epub 2009 Jan 14. PubMed PMID: 19144656; PubMed Central PMCID: PMC2635408.

110: Palandri F, Testoni N, Luatti S, Marzocchi G, Baldazzi C, Stacchini M, Castagnetti F, Breccia M, Specchia G, Pane F, Saglio G, Martinelli G, Baccarani M, Rosti G. Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. *Leuk Lymphoma.* 2009 Jan;50(1):114-8. doi: 10.1080/10428190802492415. PubMed PMID: 19125382.

111: Casnici C, Volpe G, Lattuada D, Crotta K, Kuka M, Panuzzo C, Mastrotto C, Tonon G, Fazio VM, Saglio G, Marelli O. Out of frame peptides from BCR/ABL alternative splicing are immunogenic in HLA A2.1 transgenic mice. *Cancer Lett.* 2009 Apr 8;276(1):61-7. doi: 10.1016/j.canlet.2008.10.032. Epub 2008 Dec 4. PubMed PMID: 19062160.

112: Breccia M, Cilloni D, Cannella L, Stefanizzi C, Tafuri A, Fama A, Santopietro M, Saglio G, Alimena G. Isolated molecular relapse in FIP1L1-PDGFRalpha hypereosinophilic syndrome after discontinuation and single weekly dose of imatinib: need of quantitative molecular procedures to modulate imatinib dose. *Cancer Chemother Pharmacol.* 2009 May;63(6):1161-3. doi: 10.1007/s00280-008-0858-8. Epub 2008 Nov 7. PubMed PMID: 18989670.

113: Walz C, Score J, Mix J, Cilloni D, Roche-Lestienne C, Yeh RF, Wiemels JL, Ottaviani E, Erben P, Hochhaus A, Baccarani M, Grimwade D, Preudhomme C, Apperley J, Martinelli G, Saglio G, Cross NC, Reiter A; European LeukemiaNet. The molecular anatomy of the FIP1L1-PDGFRalpha fusion gene. *Leukemia.* 2009 Feb;23(2):271-8. doi: 10.1038/leu.2008.310. Epub 2008 Nov 6. PubMed PMID: 18987651.

Garl